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ABSTRACT 
Macroautophagy Modulates Synaptic Function in the Striatum 
Ciara A. Torres 
 
The kinase mechanistic target of rapamycin (mTOR) is a regulator of cell growth and survival, 
protein synthesis-dependent synaptic plasticity, and macroautophagic degradation of cellular 
components. When active, mTOR induces protein translation and inhibits the protein and 
organelle degradation process of macroautophagy. Accordingly, when blocking mTOR activity 
with rapamycin, protein translation is blocked and macroautophagy is induced. In the literature, 
the effects of rapamycin are usually attributed solely to modulation of protein translation, and not 
macroautophagy.  
 
Nevertheless, mTOR also regulates synaptic plasticity directly through macroautophagy, and 
neurodegeneration may occur when this process is deficient. Macroautophagy degrades long-
lived proteins and organelles via sequestration into autophagic vacuoles, and has been implicated 
in several human diseases including Alzheimer’s, Huntington’s and Parkinson’s disease. Mice 
conditionally lacking autophagy-related gene (Atg) 7 function have been exploited to investigate 
the role of macroautophagy in particular mouse cell populations or entire organs. These studies 
have revealed that the ability to undergo macroautophagic turnover is required for maintenance 
of proper neuronal morphology and function. It remained unknown, however, whether it also 
modulates neurotransmission.  
 
We used the Atg7-deficiency model to explore the role of macroautophagy in two sites of the 
basal ganglia; 1) the dopaminergic neuron, and 2) the direct pathway medium spiny neuron. 
Briefly, we treated mice with rapamycin, and then examined whether an observed effect was 
present in control animals, but absent in macroautophagy-deficient lines. We found that 
rapamycin induces formation of autophagic vacuoles in striatal dopaminergic terminals, and that 
this is associated with decreased tyrosine hydroxylase (TH)+ axonal profile volumes, synaptic 
vesicle numbers, and evoked dopamine (DA) release. On the other hand, evoked DA secretion 
was enhanced and recovery was accelerated in transgenic animals in which the ability to undergo 
macroautophagy was eliminated in dopaminergic neurons by crossing a mouse line expressing 
Cre recombinase under the control of the dopamine transporter (DAT) promoter with another in 
which the Atg7 gene was flanked by loxP sites. Rapamycin failed to decrease evoked DA release 
or the number of dopaminergic synaptic vesicles per terminal area in the striatum of these mice. 
Our data demonstrated that mTOR inhibition, specifically through induction of macroautophagy, 
can rapidly alter presynaptic structure and neurotransmission. 
 
We then focused on elucidating the role of macroautophagy in dopaminoceptive neurons, the DA 
1 receptor (D1R)-expressing medium spiny neuron. Mice were confirmed to be D1R-specific 
conditional macroautophagy knockouts as assessed by p62 aggregate accumulation in D1R-rich 
brain regions (striatum, prefrontal cortex, and the anterior olfactory nuclei), and by analysis of 
colocalization of Cre recombinase and substance P. Marked age-dependent differences in the 
presence of p62+ aggregates were noted when comparing the dorsal vs. ventral striatum, and at 
different ages. We found that the size of striatal postsynaptic densities (PSDs) are modulated by 
Atg7, as mutant mice have significantly larger PSDs. Surprisingly, we also observed an increase 
in DAT immunolabel in the dorsal striatum, which suggests that apart from increasing synaptic 
strength, lack of macroautophagy in postsynaptic neurons could indirectly lead to functional 
consequences in presynaptic dopaminergic function.  
 
Given the newly elucidated role of macroautophagy in modulating a number of pre- and post- 
synaptic properties, we then explored the potential implications of this process in mediating the 
effects of synaptic plasticity, specifically to that induced by recreational drugs. An array of 
studies demonstrates that drugs of abuse induce numerous forms of neuroplasticity in the basal 
ganglia. Among these changes, rodents that are chronically treated with psychostimulants show 
increases in dendritic spine density in striatal medium spiny neurons. Little is known about the 
molecular mechanisms underlying medium spiny neurons gaining more spines in response to 
psychostimulants. Also, most data, such as involvement of both the D1R and N-methyl-D-
aspartic acid (NMDA) receptors, stems from studies using cocaine, and not amphetamine, 
although a single injection of cocaine has been shown to increase medium spiny neuron spine 
density, whether acute amphetamine is capable to do so remains to be elucidated. This is an 
attractive avenue of research to follow given that amphetamines are used recreationally, abused, 
but unlike cocaine, prescribed for attention deficit hyperactivity disorder and narcolepsy 
(reviewed in Heal et al., 2013). 
 
A myriad of studies has implicated these two proteins in spinogenesis, spine maturation and 
maintenance, and neuroplasticity. In addition, several studies have demonstrated an association 
between levels of PSD95 and spine density in various brain regions. Before characterizing the 
role of mTOR and macroautophagy in psychostimulant-induced plasticity, we examined if an 
acute injection of amphetamine at multiple doses (1-30 mg/kg) and times of collection after 
treatment (1-48 hr) influences PSD95 and Homer1b/c in the striatum of wild-type mice by 
western blotting. We found that amphetamine failed to robustly modify levels of either protein in 
the striatum.  
 
Our data raises several possibilities, including the possibility that unlike cocaine, acute regimens 
of amphetamine might not regulate spine density in the striatum, and that, it is crucial to examine 
their effects separately. Finally, this work now provides a starting point to undertake the study of 
how acute amphetamine affects macroautophagic machinery that regulates molecular, 
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The Striatum: Convergence of the Basal Ganglia and Limbic System 
Medium spiny neurons are ɤ aminobutyric acid (GABA)ergic cells that constitute the 
overwhelming majority of the cells in the striatum, and in rodents are classified as part of the 
“direct/go” or “indirect/no-go” pathway (Kemp and Powell, 1971; Matamales et al., 2009). A 
tightly regulated interplay between these two pathways results in action and movement selection. 
Both pathways play a crucial role in motor control, learning, and reward (Lobo, 2009).  
 
Figure 1.1 Organization of striatal afferents The striatum can be subdivided into two main 
regions: the dorsal and ventral striatum, both innervated by the cortex and midbrain. The dorsal 
striatum receives glutamatergic input (in red) from motor and associative cortices, and forms part 
of the basal ganglia, whereas the ventral striatum receives its glutamatergic input from, and is 
part of, the limbic system. This input consists of the prefrontal cortex, hippocampus and 
amygdala. Dopaminergic input (in blue) from the substantia nigra compacta and ventral 
tegmental area innervate the dorsal and ventral striatum, respectively. Not shown are additional 




The direct pathway is mostly composed of medium spiny neurons that express the D1R. As part 
of the classic basal ganglia loop controlling movement, dopaminergic neurons from the 
substantia nigra compacta (SNc) innervate medium spiny neurons, including those that express 
D1R, in the dorsal striatum. Motor symptoms such as slowness of or uncontrolled movement, 
postural instability, rigidity, and tremor arise from complex molecular and circuit events 
(Figures 1.1 and 1.2). Recently, the advent of optogenetics has enabled researchers to test how 
individual neuronal subpopulations in the basal ganglia contribute to both normal and 
pathological behaviors. In general, optogenetics consists of expressing light-sensitive ion 
channels in specific neuronal subpopulations (reviewed in Yizhar et al., 2011). When light is 
applied, and if the light-sensitive channel allows positive ions into the cell, cation entry will 
induce an action potential. Notably, Kravitz et al. (2010) recently used this technique to 
demonstrate that stimulation of dorsal striatum D1R+ medium spiny neurons is sufficient to 
promote movement. Furthermore, diphtheria toxin-mediated ablation of these neurons is also 
sufficient to induce an array of motor impairments (Gantois et al., 2007).  
 
On the other hand, stimulation of dorsal striatum D2R-expressing medium spiny neurons, the 
GABAergic “indirect” pathway, stops ongoing movement and decreases overall locomotion 
(Kravitz et al., 2010). Progressive neurodegeneration of these neurons also results in a movement 
disorders: Huntingon’s disease. The gene that for the protein huntingtin contains a cytosine-
adenine-guanine (CAG) repeat region, which encodes a chain of the amino acid glutamine 
known as a polyglutamine tract. When genetic mutations cause the length of the polyglutamine 
tract is beyond a certain length, huntingtin protein forms insoluble aggregates that accumulate 
into cytosolic inclusion bodies. Huntingtin aggregates show an initial accumulation of in D2R+ 
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medium spiny neurons in the dorsal striatum while the ventral striatum remains largely preserved 
(reviewed in Vonsattel, 2008).  
 
Figure 1.2 Medium spiny neuron direct and indirect pathways The D1R+ direct (gray circle) 
and DA 2 receptor (D2R)+ indirect (black circle) pathway in both the dorsal and ventral striatum 
send their axonal terminals to different basal ganglia regions. The direct pathway sends 
inhibitory GABAergic (in black) projections to the substantia nigra reticulata (SNr) and internal 
globus pallidus (GPi) where they synapse onto a second set of GABAergic neurons. These then 
send their terminals to the thalamus. The resulting effect on this structure is its disinhibition 
(glutamatergic projections in red), followed by stimulation of the cortex which ultimately “tell” 
specific parts of the body to move. Note the direct pathway has direct contact to the SNr/GPi. 
Meanwhile the indirect pathway does not, and instead, goes to the external globus pallidus (GPe) 
to the subthalamic nucleus (STN). Therefore, stimulation of the indirect pathway serves to 
inhibit the thalamus and cortex.  
 
Control of direct and indirect pathway activity in the striatum depends on modulationt of 
dopaminergic receptors that are differentially coupled to downstream effectors (reviewed in 
Surmeier et al., 2007). Briefly, D1R is positively coupled to adenylyl cyclase, which produces 
cAMP production and leads to stimulation of PKA and other changes that result in activation of 
the direct pathway. For example, D1R stimulation enhances both surface expression and 
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conductance of glutamatergic ionotropic receptors. D2Rs, on the other hand, are negatively 
coupled to adenylyl cyclase. Therefore, their stimulation results in inhibition of the indirect 
pathway. Understanding the role of DA is further complicated by its action on other 
dopaminergic receptors, their presence in presynaptic terminals, and the anatomical subdivisions 
of the striatum. 
 
The ventral striatum, which includes nucleus accumbens, also contains a large population of 
D1R medium spiny neurons. The dorsal striatum receives glutamatergic input from the motor 
and sensory cortex, and the thalamus, whereas the ventral striatum is innervated by the limbic 
system. Receiving dopaminergic inputs from the ventral tegmental area (VTA; as opposed to the 
SNc), this striatal region has been implicated in reward (Haber and Knutson, 2010). 
Interestingly, however, optogenetic stimulation of the dorsal striatal direct pathway is sufficient 
to induce conditioned place preference when administered non-contingently and self-stimulation 
(Kravitz et al., 2012). Conditioned place preference is one of the most used methods to 
determine whether a certain stimulus is rewarding (reviewed in Bardo and Bevins, 2000). 
Conditioning involves presenting the animal with an unconditioned stimulus (dorsal striatal 
direct pathway optogenetic stimulation, in this case) in one environment (chamber with black 
walls) on day 1, followed by a control stimulus in a different environment (chamber white walls) 
on day 2. This cycle is repeated several times. These two chambers are separated by a central 
neutral zone which has controlled access to both chambers. On the trial day, the animal is given 
access to both chambers, and the time voluntarily spent in each is measured. It is implied that if 
animals spend a longer amount of time is the environment that was paired with the 
unconditioned stimulus, it is because they find that stimulus to be rewarding. Self-stimulation, on 
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the other hand, requires an animal to perform an action, such as pressing a lever, which results in 
delivery of light to the neurons of interest. In order for this stimulus to be considered reinforcing, 
animals must choose to press the lever that results in self-stimulation significantly more than a 
control lever.  
 
Altogether, the experiment by Kravitz et al., (2010) suggests that direct stimulation of the dorsal 
striatum direct pathway is sufficient to experience reward and to reinforce behavior in mice. 
These data are added to the body of literature that indicates that additional regions, even apart 
from the nucleus accumbens within the striatum, are involved in mediating reward and 
reinforcement. Thus, not only is it crucial to examine these other areas, but to study how 
molecular manipulations affect whole animal behavior. 
 
The Kinase mTOR Regulates Macroautophagy 
Cell homeostasis, including in the brain, is achieved by maintaining a controlled balance 
between protein production, degradation and recycling. Macroautophagy is an important 
regulatory mechanism by which the cell degrades cytosolic material by using a double 
membrane structure called the autophagosome. The origin of the lipids that contribute to, and the 
site of autophagosome formation has been a topic of controversy, with separate studies reporting 
the source to be the endoplasmic reticulum, the mitochondrion, or the plasma membrane 
(Cuervo, 2010). It may be possible that the main source of autophagosomal lipids may vary as a 
function of which signals are competing to initiate the early steps required for macroautophagy. 
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Independently of its origin, the autophagosome engulfs cytoplasmic macromolecules and 
organelles, and has to fuse with the lysosome in order to degrade them.  
 
Figure 1.3 Low mTOR activity induces autophagosome formation (a.) When active, mTOR 
directly phosohrylates Atg13. Phospho-Atg13 is then unable to associate with Atg1 and initiate 
the early steps of autophagosome formation. When mTOR is inactive, Atg13 remains 
unphosphorylated it can bind to Atg1 and stimulate its catalytic activity. This recruits additional 
proteins involved in constructing the autophagosome. (b.) Atg7 (in gray) plays a crucial role in 
the ubiquitin-like conjugation of both Atg8 (LC3) and Atg12. Cytosolic LC3, also known as 
LC3i, is cleaved by Atg4 to expose a glycine residue. Atg7 and Atg3, acting as E1- and E2-like 
enzymes respectively, covalently bind the lipid phosphatidylethanolamine to LC3i. The E3-like 
Atg5-Atg12-Atg16 protein complex is also required for this reaction. The LC3i-PE molecule is 
known as LC3ii, and is inserted into the outer and inner membrane before autophagosome 
closure. LC3ii remains attached to these membranes until it is either degraded by the lysosome or 
recycled back to LC3i by Atg4. 
 
Autophagosome formation, hence macroautophagy, is regulated by mTOR, a kinase that as part 
of the mTOR complex 1 (mTORC1), suppresses macroautophagy via direct phosphorylation of 
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Atg13 (Kamada et al., 2010). When mTOR activity is low, Atg13 remains unphosphorylated. In 
this state, Atg13 can form a multimeric complex with Atg1 and induce its catalytic activity. This 
initiates the recruitment of additional Atg genes and a cascade of reactions that leads to 
autophagosome formation (Figure 1.3a; reviewed in Nakatogawa et al., 2009 and Kroemer et 
al., 2010). Briefly, further maturation requires formation of phosphatidylinositol-3-phosphate 
(PI3P) by class III phosphoinositide 3 kinase-containing Beclin1 multiprotein complex. Two 
ubiquitin-like conjugation systems are involved in the last steps of autophagosome formation; the 
conjugation of Atg8 (commonly referred to as microtubule-associated protein 1A/1B-light chain 
3 or “LC3” in mammals, and used hereafter) and of Atg12. Atg7 participates as an ubiquitin-
activating enzyme-like enzyme in these two parallel pathways with the final purpose of inserting 
LC3 into the growing membrane of the autophagosome (Figure 1.3b). These two systems then 
cooperate to finalize autophagosome closure around cytosolic material and debris. 
 
The bulk of macroautophagy occurs in a non-selective manner in which the autophagosome 
encircles whatever is in its vicinity. However, it is now clear that a significant proportion of what 
enters this organelle is delivered there using a cargo-selective mechanism. Recognition of 
macroautophagic cargo is achieved by particular adaptor proteins that, in turn, interact with poly-
ubiquitinated components in the cytosol. For example, in response to mitochondrial damage, 
PINK1 is poly-ubiquitinated on a lysine residue on position 63 [in contrast to position 48, which 
is recognized by the proteasome (reviewed in Nagy and Dikic, 2010)] and identified by p62, 
which then targets the mitochondrion to macroautophagic degradation, termed “mitophagy” 
(Geisler et al., 2010). This is mediated through a direct interaction between p62 and LC3 
(Komatsu et al., 2007b). Therefore, p62, and other adaptor proteins [i.e. neighbor of breast 
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cancer 1, early onset (Nbr1) and autophagy-linked FYVE protein (Alfy)] confer the 
macroautophagic machinery the ability to work together with the proteasome in maintaining 
quality control conditions in the cell.  
 
Macroautophagy in the Neuron 
The importance of macroautophagy, both selective and general, is exemplified by the effects of 
its dramatic dysfunction in neurodegenerative disease. Although a considerable proportion of the 
literature in rodents focuses on the liver, essentially all tissues studied have tested positive for the 
presence of autophagosomes (Mizushima et al., 2004). This indicates that macroautophagy is 
functional throughout the whole body. Two main methods have been used to determine whether 
particular cells are capable of activating macroautophagy.  
 
First, starvation communicates to the cell that it is not receiving a steady supply of nutrients, 
which blocks mTOR, and induces macroautophagy. Therefore, this simple method has been 
exploited to characterize the tissue and organ distribution of autophagic vacuoles following a 
period of food restriction. Despite detection of autophagosomes in brains of diseased humans and 
animals, whether macroautophagy had a physiological role in the central nervous system (CNS) 
was unclear until recently (reviewed in Larsen and Sulzer, 2002b). The belief that 
macroautophagy was absent in the brain stemmed, in part, from the fact that autophagosomes 
were not observed there in response to starvation (Mizushima et al., 2004). Several research 
groups, however, have reported that macroautophagy is present in the brain during normal 
conditions, including starvation (Alirezaei et al., 2010; Nixon et al., 2005), and that the brain is 
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not exempt from the physiological effects of prolonged nutrient deprivation. Neurons, 
nevertheless, do possess multiple mechanisms that confer an advantage over other cells during 
times of low nutrient supply, including glial support (Boland and Nixon, 2006). Data from a 
recent study by Wei et al. (2013), however, demonstrates that ischemia increases the number of 
autophagosomes (LC3+ puncta) in the brain. This effect was larger in a mouse model of diabetes. 
Therefore, conditions that significantly limit the supply of oxygen and glucose to the brain reveal 
the presence of macroautophagy in this organ. Finally, in diseases that induce these conditions, 
this knowledge could be exploited to determine whether modulating macroautophagy will 
ameliorate any of the effects in the brain.  
 
The second method has consisted of characterizing the effects of removing the ability of cells to 
form autophagosomes, therefore blocking macroautophagy. This method has used Atg5 or Atg7 
as the molecular target and has the advantage of removing macroautophagy without directly 
affecting other pathways downstream of mTOR. The first report to use this method to study 
macroautophagy in the brain introduced a mouse line where Atg5 was conditionally knocked out 
of neuronal cells by using Nestin promoter-driven expression of Cre recombinase (Hara et al., 
2006). These mutants exhibit an array of motor impairments including limb-clasping and 
tremors. Purkinje and pyramidal cells were reported to be prominently affected as seen by the 
apoptotic death in the cerebellum and cortical regions. Interestingly, an age-dependent 
accumulation of ubiquitin+ aggregates was noted in multiple other brain regions including the 
striatum. Axonal swelling was also observed in a number of regions. Use of the same Nestin 
promoter to remove Atg7 resulted in an, in essence, identical set of phenotypes (Komatsu et al., 
2006; 2007). Whether these phenomena were directly or indirectly, through secondary effects, 
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caused by lack of macroautophagy is not known. Notwithstanding, these studies indicated that 
neuronal types differ in their vulnerability to lack of macroautophagy and opened the door to 
generate a series of experiments that would begin to elucidate the role of macroautophagy in 
neuronal make-up, morphology and function. 
 
Macroautophagy and Neuroplasticity 
A number of lines of evidence suggest that mTOR, and perhaps degradation via 
autophagosomes, is involved in neuronal plasticity. First, mTOR modulates soma, neurite and 
synapses size (Li et al., 2010; Mazei-Robison et al., 2011). This is accompanied by functional 
changes in electrophysiological and electrochemical properties. Second, learning and memory 
consolidation in animals is dependent on mTOR activity (Garelick and Kennedy, 2011; Jaworski 
and Sheng, 2006). Finally, the actions of some drugs of abuse (Bailey et al., 2010; Li et al., 
2010; Mazei-Robison et al., 2011; Narita et al., 2005; Wang et al., 2010; Wu et al., 2010) is 
dependent on mTOR activity. This body of literature clearly implicates mTOR in many forms of 
neuroplasticity, and the behaviors that depend on it. However, the method most commonly 
employed in these studies consisted of applying chronic (single or multiple daily injections for 
days to weeks) treatments with direct, such as rapamycin or indirect mTOR inhibitors.  
 
Rapamycin, however, is not a specific modulator of any particular of function of mTOR, but 
rather affects all its downstream effects. Rapamycin forms an intracellular complex with 
FKBP12, which then binds to mTOR's FKBP-rapamycin binding (FRB) domain and inhibits its 
function (Sehgal, 2003). Although mTOR-dependent translation has been shown to play a crucial 
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role in neuroplasticity (Santini and Klann, 2011), careful analysis of the possible function of 
macroautophagic degradation of cytosolic components in mammalian neuroplasticity had to wait 
until the development of the mutants discussed above.  
 
A number of abnormalities in the mTOR pathway, including in autophago-lysosomal system, 
have been observed in neurodegenerative disorders including Alzheimer’s, Huntington’s and 
Parkinson’s disease (reviewed in Bove et al., 2011). In fact, treatment with rapamycin can 
attenuate neurodegeneration in animal models of these diseases. In addition, synaptic 
components have been colocalized with autophagosomes (Matsuda et al., 2008; Vogiatzi et al., 
2008; Rowland et al., 2006), suggesting that macroautophagy. These data suggest that 
macroautophagy, and its dysfunction, could have a role in regulating synaptic release and 
neurotransmission both in normal and pathological states. This data suggests that these chronic 
impairments in macroautophagy participate in the pathological features that could cause some 
neuropsychiatric diseases. In Chapters 2 and 3, we recently address this question by creating 
mouse lines that selectively remove macroautophagy from two separate striatal systems.  
 
In the first series of studies, we removed Atg7 function in dopaminergic neurons (Hernandez et 
al., 2012; Torres and Sulzer, 2012). In brief, we found that chronic lack of macroautophagy 
resulted in elevated evoked DA release and recovery in the dorsal striatum. We postulated that 
this was mediated by an increase in size and higher density of synaptic vesicles in dopaminergic 
terminals of conditional knockout (CKO) mice. Acute induction of macroautophagy by 
rapamycin caused the opposite, a decrease in dopaminergic axonal profile size and increase in 
synaptic vesicle density, and its action was not present Atg7-deficient animals, which indicates 
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that macroautophagy, and not another mTOR-regulated process was responsible for the effects of 
rapamycin on presynaptic function and neurotransmission. While we found no behavioral 
abnormalities in young adults, older mutants exhibit a number of age-dependent impairments in 
motor control (Ahmed et al., 2012; Inoue et al., 2013). Due to this defect being mediated through 
neurodegeneration of dopaminergic neurons, this mouse line could serve as a novel animal 
model of Parkinson’s disease.   
 
In another set of studies, we asked whether macroautophagy could also have a role in 
postsynaptically in the striatum. We hypothesized that as macroautophagy had affected 
morphological, composition and functional properties presynaptically in dopaminergic neurons, 
it may do so in postsynaptic structures in the medium spiny neuron. Thus, we generated CKO of 
Atg7 in D1R+ neurons and began to examine its role in the direct pathway. Specifically we 
focused on PSD size and the density of asymmetric, presumed glutamatergic, synapses, both of 
which are correlated with synaptic strength and synapse number respectively. Interestingly, we 
observed an increase in PSD size in the absence of a change in synapse density in young adults. 
Thus, apart from modulating presynaptic activity, macroautophagy is also involved in controlling 
the postsynaptic microenvironment. 
 
Our preliminary data suggests that these mutants might exhibit a non-cell autonomous effect on 
dopaminergic innervation of the striatum. Whether these alterations are accompanied by 




Macroautophagy and Recreational Drugs: A Potential Relationship 
As mentioned above, some recreational drugs exert their effects in part by modifying mTOR 
activity. Dependence on mTOR activity has been observed for morphine, ketamine and some 
psychostimulants. Cocaine increases mTOR activity in the VTA and nucleus accumbens, and 
pre-treatment with rapamycin blocks the expression of locomotor sensitization to this drug 
(Bailey et al., 2010; Wu et al., 2011). Behavioral sensitization can be described as an increase in 
the effects of a stimulus upon its re-administration. In the case of psychostimulants, this 
phenomenon includes, but is not limited to, locomotor sensitization (reviewed in Pierce and 
Kalivas, 1997). Sensitization to the development of conditioned place preference by 
methamphetamine has also been reported to be blocked by rapamycin (Narita et al., 2005). Li et 
al. (2010) reported that ketamine increases mTOR activity in the prefrontal cortex in an α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-dependent manner, which leads to a 
rapamycin-sensitive increase in spine density and mini excitatory postsynaptic current (mEPSC) 
frequency. As previously stated, these studies did not distinguish whether macroautophagy 
specifically was involved in these alterations. In another study, morphine was demonstrated to 
induce autophagosome formation and macroautophagic degradation in the hippocampus (Zhao et 
al., 2010). This is interesting in light of the fact that multiple studies have shown that morphine 
can reduce neuronal size, dendritic complexity and spine density in the hippocampus, VTA and 
other brain regions (Mazei-Robison et al., 2011; Robinson and Kolb, 2004). Whether induction 
of macroautophagy by morphine is required to mediate any of its effects on neuronal 




In addition, activation of receptors that are stimulated both directly and indirectly (DA and 
glutamate receptors, respectively) by amphetamine also increased mTOR activity (Santini and 
Klann, 2011). Robinson and Kolb (1997) first showed that a 5-week long escalating dose 
regimen (2 i.p. injections on day 0-5, undisturbed on day 6-7) of cocaine or amphetamine, 
followed by a 38 day withdrawal period, increases spine density of medium spiny neurons in the 
nucleus accumbens (reviewed in Robinson and Kolb, 2004). It was later shown that this effect is 
not specific to the nucleus accumbens; similar results have been observed in other brain regions, 
including the dorsal striatum (Jedynak et al., 2007; Li et al., 2003). Recent studies have shown 
that neither a long withdrawal period, nor weeks of daily injections are required for these effects 
(Dobi et al., 2011; Sarti et al., 2007; Shen et al., 2009). However, the acute effects of 
amphetamine on spine density, and on the proteins that are responsible for maintaining proper 
spine number, shape and function have not been studied systematically. 
 
Many proteins come together to form the PSD (reviewed in Boeckers, 2006). Scaffold proteins 
link neurotransmitter receptors embedded in the membrane to intracellular messengers, 
transforming the PSD into a highly organized functional signaling complex. PSD95 is one of the 
most abundant components of the PSD, and is among the earliest proteins to cluster at synaptic 
sites (Okabe et al., 2001; Rao et al., 1998). Indeed, the appearance of PSD95 at spines coincides 
with stabilization of previously transient dendritic structures (De Roo et al., 2008). Levels of this 
protein are associated with measures of synaptic strength (PSD size) and synapse number (PSD 
number by area) in several brain regions (Comery et al., 1995; Esparza et al., 2012; Li et al., 
2010; Nithianantharajah et al., 2004; Pal and Das, 2013; Schnell et al., 2002; Toda et al., 2010; 




Based on data from previous studies, we hypothesized that amphetamine would increase spine 
density in the striatum, and that this would lead to a dose and time dependent increase in levels 
of PSD95 as assessed by western blotting. Presumably, this increase would be occluded in our 
direct pathway medium spiny neuron macroautophagy-deficient mutants, as there should already 
be an increased number of dendritic spines. Note however, that at 2 months of age, these mice 
had as much PSDs as age-matched controls (CTLs). We constructed dose and time response 
curve on total striatal levels of PSD95 and detected a weak/variable effect of amphetamine at 10 
mg/kg at 24 hr after administration. As we proposed to test whether effects of amphetamine 
require macroautophagy, and we found that its effect on PSD95 is weak, we have decided that 
future studies will focus on testing more robust phenomena. 
 
We developed, and continue to characterize the macroautophagy-deficient mouse lines discussed 
in Chapters 2 and 3 to be address the specific role of macroautophagy in the action of drugs of 
abuse. In Chapter 4 we focus on amphetamine, and how in vivo administration may affect levels 










The overall goal of this thesis is to investigate how macroautophagy modulates presynaptic and 
postsynaptic properties in the striatum. Using mouse models that lack macroautophagy in 
dopaminergic neurons that innervate and in medium spiny neurons that exit the striatum, the 
overall hypothesis of this work is: 
 
Macroautophagy has important functional implications in neuronal homeostasis, neuroplasticity 
and is altered in several neurodegenerative diseases. We hypothesized that mTOR-dependent 
macroautophagy would have a role in modulating presynaptic (in dopaminergic terminals) and 
postsynaptic (in medium spiny neuron PSDs) properties in the striatum. 
 
 









Macroautophagy and the nigrostriatal synapse 
Note: The work presented on this chapter was done in collaboration with Drs. Daniela 
Hernandez (see Figures 2.3 and 2.4) and Carolina Cebrián Parajon (see Figure 2.5a-c). Dr. 
Olga Yarygina (see Figure 2.1) and Wanda Setlik (electron microscopy): from the Dr. 
Robert Burke and Michael Gershon labs, respectively, also contributed.  
 
INTRODUCTION 
mTOR regulates protein synthesis (Huang and Manning, 2009) and degradation (Cuervo, 2004). 
mTOR activity enhances protein synthesis via participation in the complex mTORC1, which 
leads to phosphorylation of ribosomal subunit S6 (S6) and eukaryotic translation initiation factor 
4E-binding protein (4EBP) (Huang and Manning, 2009). mTORC1 also phosphorylates Atg13, 
inhibiting Atg1, which is required for the induction of macroautophagy (Kamada et al., 2010). 
mTOR activity, therefore, both enhances protein synthesis and inhibits cellular degradation 
pathways. 
 
In the nervous system, mTORC1 activity stimulates protein synthesis-dependent synaptic 
plasticity and learning (Huang and Manning, 2009; Long et al., 2004; Richter and Klann, 2009). 
Most studies on cellular and neuronal functions of mTOR use rapamycin, an inhibitor that, when 
bound to FKBP12, interacts with mTOR’s FRB domain and prevents mTOR from binding 
raptor, a component of the mTORC1 complex (Dowling et al., 2010). Rapamycin blocks axonal 
hyperexcitability and synaptic plasticity in cellular models of injury, as well as learning and 
memory, by inhibiting protein synthesis (Hu et al., 2007; Weragoda and Walters, 2007). 
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Macroautophagy is a highly conserved cellular degradative process in which proteins and 
organelles are engulfed by autophagic vacuoles (AVs) that are subsequently targeted for 
degradation in lysosomes. It is possible that degradation of pre- or postsynaptic components 
could contribute to plasticity: for example, local mTOR inhibition might elicit autophagic 
degradation of synaptic vesicles, providing a means of presynaptic depression. We therefore 
explored whether mTOR-regulated degradation of proteins and organelles via macroautophagy 
alters synaptic function and morphology. To do so, we generated transgenic mice in which 
macroautophagy was selectively inactivated in DA neurons. These neurons are functionally 
deficient of Atg7, an E1-like enzyme that conjugates LC3 to phospholipid and Atg5 to Atg12; 
steps that are necessary for AV formation (Martinez-Vicente and Cuervo, 2007). We chose to 
specifically delete Atg7 to abolish macroautophagy and the formation of AVs because, in 
contrast to Atg1, it is not thought to directly regulate membrane trafficking (Wairkar et al., 
2009). 
 
We chose to examine presynaptic structure and function in the DA system because (1) in the 
acute striatal slice preparation, DA axons are severed from their cell bodies but continue to 
synthesize, release, and reaccumulate neurotransmitter for up to 7 hr, allowing us to clearly focus 
on axonal autophagy, and (2) electrochemical recordings of evoked DA release and reuptake in 
the striatum provide a unique means to measure CNS neurotransmission with millisecond 
resolution that is independent of postsynaptic responses. 
 
We found that (1) chronic macroautophagy deficiency in DA neurons resulted in increased size 
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of axon profiles, increased evoked DA release, and more rapid presynaptic recovery within the 
striatum; (2) in mice with intact macroautophagy, mTOR inhibition with rapamycin acutely 
increased AV formation in axons, decreased the number of synaptic vesicles, and depressed 
evoked DA release; and (3) rapamycin had no effect on evoked DA release and synaptic vesicles 
in DA neuron-specific macroautophagy-deficient mice. We conclude that mTOR-dependent 




Animals. DAT-Cre+/-; ATG7fl/fl (CKO) mice were generated by flanking exon 14 of the Atg7 
gene with loxP sites (Komatsu et al., 2005) and mating the ATG7fl/fl  line with mice carrying Cre 
recombinase under the control of the DAT promoter (Zhuang et al., 2005) so that expression is 
restricted to dopaminergic neurons. Because the mutant mice have a single functional copy of 
DAT, we used DAT-Cre+/- animals as CTLs; these animals express two copies of wild-type Atg7 
and a single functional copy of DAT. All animals were in a C57BL/6 background. Wild-type 
C57BL/6 male mice aged 8-10 weeks were purchased from Jackson Labs (Bar Harbor, ME). 
Mice were housed in groups of 2-5 in a 12:12 hr light-dark cycle and given access to food and 
water ad libitum. All procedures were approved by and performed in accordance with the 
Institutional Animal Care and Use Committee at Columbia University.  
 
Nonradioactive in situ hybridization. Tissue was mounted in optimal cutting temperature 
medium and frozen sections (14 µm) were prepared with a cryostat and mounted on Superfrost 
Plus slides (Fisher 12550-15). They were kept at -80°C until used. Tissue was fixed in freshly 
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prepared 4% paraformaldehyde, 0.1 M phosphate buffer saline (PBS) for 10 min at room 
temperature. Samples were then washed 3 times for 5 min in PBS. Sections were then treated 
with a pre-hybridization solution as previously described (Burke et al., 1994) for 2 hr at room 
temperature. Sections were then covered with hybridization solution and incubated overnight at 
68ºC. Hybridization solution contained either anti-sense or sense Atg7 probe (Cheng et al., 2011) 
labeled with digoxigenin-UTP, prepared as per the manufacturer’s instructions (Roche 
Diagnostics). The size and integrity of labeled probe were confirmed by gel electrophoresis. 
After washes in 0.2x SSC at 68ºC, sections were incubated with an antidigoxigenin antibody 
(Roche) at 1:5000 overnight at 4ºC. After additional washes, sections were incubated with a 
developing solution containing BCIP/NBT (Promega) overnight at room temperature in the dark. 
Sections were washed and coverslipped with aqueous mounting medium (DAKO). 
 
In vivo perfusion and sample preparation for electron microscopy. Mice were anesthetized 
with ketamine/xylazine, and a needle connected to a perfusion pump was inserted into the left 
ventricle. Saline containing heparin was perfused at 4 ml/min for 5 min to wash out the blood. 
2% glutaraldehyde was perfused at 4 ml/min for 5 min. The fixed brain was then carefully 
removed from the skull. The striatum was dissected and post-fixed in 2% glutaraldehyde for 1 hr 
at room temperature. Sections (40-50 µm) were cut with a vibratome and incubated for 30 min at 
room temperature in a blocking solution containing 10% normal goat serum in PBS. The sections 
were incubated for 48 hr at 4°C with a rabbit antibody to TH (diluted 1:2000; Protos Biotech) in 
PBS containing 10% goat serum. Bound primary antibodies were located with biotinylated 
secondary antibodies and peroxidase-labeled avidin (Vector ABC elite kit) and peroxidase 
activity was visualized with 3-3’-diaminobenzidine. The H2O2 for the DAB reaction was 
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generated with glucose and glucose oxidase to minimize tissue damage. Sections were finally 
washed with PBS, treated with 1% OsO4 for 1 hr at room temperature, washed again in PBS and 
maleate buffer (five times for 5 min) at RT and stained en bloc with 2% aqueous uranyl acetate 
on ice for 1 hr. Stained sections were dehydrated through a graded series of ethanol solutions, 
cleared with propylene oxide, and embedded in Epon 812 (Electron Microscopy Sciences). Thin 
(silver) sections were cut, picked up on copper grids, and examined with a JEOL 1200EX 
electron microscope. 
 
5-OHDA incubation. Male mice (3-6 months of age) were sacrificed and 200 µm slices 
prepared as above. Hemislices were transferred to a chamber containing oxygenated artificial 
cerebrospinal fluid (aCSF) with either DMSO or rapamycin (3 µM) in DMSO for 6.5 hr. aCSF 
contained (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO3, 2 CaCl2, 1 MgCl, 1.25 NaH2PO4 and 10 
glucose at room temperature. Slices were transferred to the following solution with 500 µM 5-
hydroxydopamine (5-OHDA; Sigma) for 0.5 hr (in mM): 10 NaCl, 2.5 KCl, 25 HEPES, 1 
NaH2PO, 2 CaCl2, 10 mM glucose, and 0.2 mg/ml ascorbic acid, and 0.16 mg/ml pargyline HCl, 
at a pH of 7.4. Slices were then rinsed three times in aCSF for 5 min each. Slices were then fixed 
in ice cold 3% sodium permanganate in aCSF for 40 min on ice. Slices were then washed three 
times for 5 min in aCSF at room temperature and then three times for 5 min in 0.9% NaCl. 
Samples were stained en bloc staining in 4% uranyl acetate on ice for 1 hr. Specimens were 
dehydrated in a graduated series of ethanols, cleared in propylene oxide, and embedded in Spurr 
medium (Ted Pella). 
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Slice preparation for electron microscopy. Additional slices (with the exception of those 
processed for 5-OHDA as above), prepared for electron microscopy (200 µm thickness) were 
placed for 7 hr in a holding chamber containing oxygenated aCSF  containing either DMSO or 
RAPA  (3 µM). They were fixed in 2.5% glutaraldehyde in 0.1M Sorensen’s buffer (pH 7.2) 
overnight and then washed with 0.1 M Sorensen’s buffer 3 times for 5 min. Slices were 
incubated in 1% OsO4 diluted in Sorensen's buffer for 1 hr. Slices were then washed in buffer 3 
times for 2 min and once in water. The slices were placed in freshly made 1% tannic acid in 
water for 15 min, followed by another wash in water. En bloc staining was performed with 1% 
uranyl acetate in water for 1 hr. Dehydration was performed in 50% and 70% ethyl alcohol for 
10 min and then in 95% and 100% three times for 10 min. Following dehydration, slices were 
incubated in 2 parts 100% alcohol to 1 part embedding medium (Ladd LX-112 & EMS 112) for 
at least 1 hr. Then they were incubated in 1:1 100% alcohol to embedding medium overnight at 
60 °C. Dishes were then drained and fresh embedding medium was added for at least 2 hr. 
 
Electrochemical recordings. Mice were sacrificed by cervical dislocation. Striatal slices were 
cut on a vibratome at a thickness of 300 µm for electrochemical experiments. Slices were placed 
in a glass holding chamber containing oxygenated aCSF at room temperature and were allowed 
to recover for at least 1 hr before the start of the experiments. Slices were incubated in 3 µM 
rapamycin or DMSO for at least 6 hr before recordings began. For cyclic voltammetry, slices 
were placed in a recording chamber and superfused with aCSF (in mM): 125 NaCl, 2.5 KCl, 26 
NaHCO3, 2.4 CaCl2, 1.3 MgSO4, 0.3 KH2PO4, and 10 glucose at 36°C. Electrical stimulation and 
recording protocols were adapted from Schmitz et al., 2001. Carbon fiber electrodes (5 µm 
diameter) were placed in the dorsal striatum, approximately 50 µm into the slice. For cyclic 
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voltammetry, a triangular voltage step (-400 mV to +1000 mV at 300 V/s vs. Ag/AgCl) was 
applied to the electrode every 100 ms. Currents were recorded using an Axopatch 200B amplifier  
(Axon  Instruments, Foster  City, CA), with a low-pass Bessel Filter setting at 5 kHz, digitized at 
25 kHz (ITC-18 board, Instrutech Corporation, Great Neck, NY). We used IGOR software for 
data acquisition (WaveMetrics, Lake Oswego, OR) with a locally written program (Dr. E. 
Mosharov, Columbia University) available at http://sulzerlab.org/download.html. Striatal slices 
were stimulated every 2 min with either a single pulse of electrical stimulation or paired stimuli 
via an Iso-Flex stimulus isolator triggered by a Master-8 pulse generator (AMPI, Jerusalem, 
Israel) using a bipolar stimulating electrode placed approximately 100 µm from the recording 
electrode. To assess single pulse (1p) evoked DA release, slices were stimulated in the dorsal 
striatum with a single pulse of electrical stimulation (0.4 mA, 1 ms duration). Three or four 
individual recordings were taken from each of 3 sites on each slice. To calculate the 1p evoked 
release from each slice all 9-12 recordings were averaged together. To obtain the paired pulse 
ratio, slices were stimulated with 2 pulses of electrical stimulation separated by interstimulus 
intervals of 1, 2, 5, 10, 20, 30, and 60 s. To calculate the paired pulse ratio, the peak from the 
second stimulation was normalized to the first. Background-subtracted cyclic voltammograms 
served to identify the released substance. The DA oxidation current was converted to 
concentration based on a calibration of 5 µM DA in aCSF after each slice. 
 
Primary neuronal cultures. Ventral midbrain (including SN and VTA) primary neuronal 
cultures were prepared from postnatal day 0–3 C57/BL6 mice. This region was dissected and 
neurons were dissociated and plated at a density of 80,000 per cm2 onto a layer of rat cortical 
glial cells grown on wells cut into 50 mm dishes on SF1C neuronal medium. Primary neuronal 
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cultures were incubated in a 5% CO2 incubator at 37°C for 5–9 days before adding any treatment 
(Rayport et al., 1992). VM neurons were incubated with either DMSO or rapamycin (200 nM, 
Sigma Aldrich) for 3.5 hr. After that time, cultures were first quickly washed in warm PBS and 
then fixed with 4% paraformaldehyde for 30 min at room temperature. Neuronal cultures were 
then washed three times with 1X PBS, and blocked for 1 hr in 1X PBS containing 10% of 
normal donkey serum (NDS; Jackson Immunoresarch). Cultures were rewashed again in 1X PBS 
and then incubated overnight at 4°C in a solution of 1X PBS [2% of NDS with two primary 
antibodies: anti-mouse tyrosine hydroxylase (TH) (1:2000, Millipore) and anti-rabbit LC3 
(1:200, Novus Biologicals)]. Cultures were washed three times with 1X PBS, incubated with 
appropriate secondary antibodies (Alexa Fluor 488 donkey anti-rabbit and Alexa Fluor 594 
donkey anti-mouse; Invitrogen) at a concentration of 1:400 and diluted in 1% of NDS 1X PBS at 
room temperature during 1 hr. Finally, cultures were washed three times in 1X PBS and stored at 
4°C. Images were collected pictures were collected on a Leica SP5 confocal microscope 
equipped with the appropriate lasers and filter sets. The number of LC3ii puncta in the soma and 
neurites was analyzed by Image J. All numerical results are reported as mean ± standard error of 
the mean (SEM) from a minimum of three independent experiments. 
 
Protein collection and western blot. After incubations, the cortex was separated from the 
striatum and discarded. Sets of 2 hemislices were collected into individual tubes and snap-frozen 
on dry ice. Tubes were stored at -80°C for 1-3 days. The striatal tissue sonicated in 100 µL of 1% 
SDS. Contents were transferred into Eppendorf tubes and boiled at 100°C for 5 min. Protein 
concentration was determined by the BCA method (Pierce). A total of 25 µg were loaded in each 
well of a 15% bisacrylamide gel and run at 180 mV for 1 hr or until the protein ladder markers 
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(Fisher) were well separated. Protein was transferred to a polyvinyledine fluoride (PVDF) 
membrane at 40 mV for 3 hr or at 10 mV overnight. Membranes were then rinsed and washed 
once in 1X TBS/0.05% Tween-20, blocked in 5% milk and incubated with the following primary 
antibodies: 1:60000 anti-mouse beta-actin (Sigma), 1:500 anti-rat DAT (Millipore), 1:1000 anti-
rabbit LC3 (Novus), 1:1000 anti-mouse porin (Mitosciences), 1:1000 anti-PSD95 (Abcam), 
1:2000 anti-mouse TH (Millipore), and 1:333 anti-mouse tomm20 (Abcam). Corresponding 
HRP-conjugated goat secondary antibodies were used at a 1:1000 concentration; anti-mouse and 
anti-rabbit (Thermoscientific), and anti-rat (Novus). Protein was detected by incubating 
membranes for 5 min with HRP substrate (Millipore), and Image J was used to determine the 
intensity of bands using actin to normalize the signal. For comparison between CTL and CKO 
lines, a pair of littermates was compared per experiment using 2-4 slices per animal, and the 
levels from each slice combined and divided by the number of slices. Each experiment was 
conducted at least three times, and presented as mean ± SEM as percent of total signal intensity 
obtained per experiment. 
 
RESULTS 
DAT-Cre+/-; Atg7fl/fl mice are confirmed dopaminergic macroautophagy conditional 
knockouts 
Atg7 mRNA was detected by in situ hybridization in the SNc and SNr in CTL animals but was 
absent in DAT-Cre+/-; Atg7fl/fl CKO mice (Figure 2.1). Atg7 mRNA was detected in the red 
nucleus (RN) and in the dentate gyrus (DG) of CKOs, further indicating cellular specificity for 
the lack of Atg7 (data not shown). Because we cannot differentiate between SN dopaminergic 
and non-dopaminergic neurons, but based on the dependence on DAT for expression, we 
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conclude that the Atg7 gene was probably effectively deleted in ventral midbrain dopaminergic 
neurons.  
 
In contrast to CNS-wide macroautophagy-deficient mice, which are smaller than CTLs, and 
begin to die around 4 weeks (Hara et al., 2006; Komatsu et al., 2006), CKO mice showed similar 
survival and weight gain as CTL mice at 2 months of age (mean weights: 22.7 ± 1.1 g and 25.2 ± 
1.6 g, respectively; p>0.05; n=6 mice per group; Student’s t-test).  
 
Figure 2.1 DAT-Cre+/-; Atg7fl/fl mice selectively lack Atg7 in dopaminergic neurons. Atg7 
transcript was detected with an RNA probe designed against nucleotides 1518-1860 of the Atg7 
gene. Atg7 mRNA was detected in the anterior SN of the CTL mouse, but not in the CKOs. The 
close anatomical correspondence between the anterior coronal SN sections from the CTL mouse 
and the CKO mouse is shown by the matching locations of the medial lemniscus (ML) and the 
medial terminal nucleus (MT). Nissl staining (blue) showed a comparable number of cells in the 
CKO and the CTL mice. 
 
 
Dopaminergic Axonal Profiles Are Larger in DAT-Cre+/-; Atg7fl/fl mice 
We examined striatal dopaminergic axonal profiles immunolabeled for TH from 2 month old 
mice by electron microscopy (Figure 2.2a). There was no difference in the number of striatal TH 
immunoreactive axonal profiles per area in CKO mice (Figure 2.2b). There was, however, an 
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increase in the fraction of total area occupied by TH+ profiles: TH+ axon profiles occupied 2.3% 
± 0.2% of the total sampled area in the striatum of CTL mice but 4.7% ± 0.5% of the area in 
CKO mice (p<0.005; Student’s t-test; >6,000 µm2 sampled per condition in 10 and 8 
micrographs, respectively; Figure 2.2c). Consistently, striatal TH+ axonal profiles from CKO 
mice (0.42 ± 0.04 µm2, n=84) were larger than profiles from CTL animals (0.29 ± 0.03 µm2, 
n=60; p<0.05; Mann-Whitney test; Figure 2.2d). We found no difference in the size of terminals 
unlabeled for TH between CTL and CKO mice (0.24 ± 0.03 µm2, n=26; 0.30 ± 0.03 µm2, n=27; 
p>0.05; Student’s t-test; Figure 2.2e).  
 
To explore the effects of mTOR inhibition and macroautophagy deficiency on the size of 
dopaminergic axonal profiles, we injected pairs of CTL and CKO mice with rapamycin (2 
mg/kg) or DMSO 36 and 12 hr prior to perfusion. Rapamycin decreased the area of TH+ striatal 
axon profiles by 32% in CTL mice but had no effect on DA terminals of the CKO mouse line 






Figure 2.2 Macroautophagy deficiency results in morphological alterations Dopaminergic 
striatal axonal projections from 2 month old male mice were identified by TH immunolabeling 
by electron microscopy. (a.) Representative electron micrographs in CTL and CKO mice. 
Arrowheads indicate TH+ axonal profiles. Scale bar is 500 nm. (b.) There was no difference in 
the number of TH+ profiles per 100 mm2 between CTL and CKO mice. (c.) The total area 
occupied by TH+ profiles in striatum from CKO was larger than in CTL mice (p<0.05; Student’s 
t-test). (d.) The average area of TH+ profiles was 45% larger in CKO (n=84) than CTL (n=61) 
(p<0.05; Student’s t-test). (e.) There was no significant difference in the size of TH+ profiles 
between CTL (n=26) and CKO (n=27) mice (p>0.05; Student’s t-test). (f.) Rapamycin (RAPA) 
in vivo (administered twice, 36 and 12 hr prior to sacrifice) decreased TH+ profiles by 32% in 
CTL mice (n=51, DMSO; n=54, RAPA), but not in CKO mice (n=116, DMSO; n=61, RAPA; 
interaction between RAPA and genotype, F=6.72; p<0.01; 2-way ANOVA). The quantified data 





Dopamine neurotransmission is altered in DAT-Cre+/-; Atg7fl/fl mice 
We used cyclic voltammetry to directly measure evoked DA release and reuptake in the striatum 
of adult mice. The peak amplitude of the signal is dependent on both neurosecretion and reuptake 
through DAT, whereas the half-life (t1/2) is a function of DAT activity (Schmitz et al., 2001). 
The amplitude of the DA signal evoked by a single pulse of electrical stimulation in CKO mice 
was 54% greater than in age-matched CTLs (n~8; 4.0 ± 0.3 and 2.6 ± 0.2 nM, respectively; 
p<0.005; Student’s t-test; Figures 2.3a and b). As CTL and CKO mice express a single 
functional copy of DAT, the signal duration in both genotypes was longer than in wild-type mice 
(mean t1/2: ~490 ms) (Schmitz et al., 2001), but the mean t1/2 of DAT signals from CTL and CKO 
slices was not different (Figure 2.4a; mean t1/2: 637 ± 51 and 662 ± 23 ms, respectively; p>0.05; 
Student’s t-test), which indicates that reuptake kinetics are similar and that the increased peak 






Figure 2.3 Evoked dopamine release in DAT-Cre+/-; Atg7fl/fl mice (a.-b.) Cyclic voltammetry 
recordings of evoked DA release from slices of dorsal striatum from CTL and CKO mice. Note 
that evoked DA release was higher in CKOs (p<0.005; Student’s t-test). (c.-d.) Representative 
traces from paired-pulse recordings at interstimulus intervals of 5–60 s from a CTL and CKO 
slice (slightly offset to aid comparison). Recovery was faster CKO than CTLs (p<0.05; repeated 
measures ANOVA). (e.) Representative traces from control (DMSO vehicle) and rapamycin-
treated (red) CTL and CKO slices. (f.) Rapamycin decreased the peak amplitude of DA signals 
in CTL striata by 25% ± 3% but decreased it by only 6% ± 6% in CKO striata (p<0.05; 2-way 




To measure the rate of presynaptic recovery, we stimulated DA release with pairs of pulses 
separated by intervals that ranged from 1 to 60 s (Schmitz et al., 2002). CKO exhibited faster 
recovery (p<0.05; repeated-measures ANOVA; Figure 2.3d), suggesting that basal 
macroautophagy can restrict synaptic transmission.  
 
We then examined effects of rapamycin on evoked DA release. Striatal slices were bisected, and 
one striatum was exposed to rapamycin (3 mM, >5.5 hr) and the other to vehicle. Rapamycin 
decreased DA release evoked by a single electrical stimulus by 25% ± 3% in CTL slices (n=7) 
and by 6% ± 6% in CKO slices (n=9; p<0.05; 2-way ANOVA; Newman-Keuls post-hoc test; 
Figures 2.3e and f). Rapamycin did not significantly alter the t1/2 of the signals from CTL 
(DMSO: 718 ± 29 ms; RAPA: 675 ± 22 ms) or CKO (control: 753 ± 23 ms; RAPA: 743 ± 32 
ms) mice (Figure 2.4a; p>0.05; 2-way ANOVA). The data indicate that the bulk of rapamycin’s 
inhibition of evoked DA release is mediated by macroautophagy. To confirm that these effects 
were not limited to CTL (DAT-Cre+/) mutants, we repeated the recordings in slices from wild-






Figure 2.4 Acute mTOR inhibition decreases evoked dopamine release, but not reuptake 
(a.) Lack of effect of rapamycin (3 µM) on the on the t1/2 of the signals in Figure 3 from paired 
striata from CTL (DMSO: 718 ± 29 ms, RAPA: 675 ± 22 ms, n=7) and CKO (753 ± 23 ms, 
RAPA: 743 ± 32 ms, n=9) mice (p>0.05, 2-way ANOVA). (b.) Representative traces from 
DMSO and rapamycin-treated wild-type slices. Evoked DA release from slices (n=10 per 
condition) from wild-type striatum incubated in aCSF containing 3 µM rapamycin was 
significantly reduced compared to controls. As observed in the CTL line (Figure 3), rapamycin 
decreased the peak amplitude of DA signals by 40% (mean peak amplitude: 3.7 ± 0.3 µM in 
DMSO vs. 2.2 ± 0.3 µM in rapamycin-treated slices).     
 
 
Effects of acute rapamycin treatment 
To examine the effect of acute mTOR inhibition on AV formation, we first exposed postnatally-
derived ventral midbrain neuronal cultures (Rayport et al., 1992) to rapamycin (200 nM, 3.5 hr). 
The macroautophagy-related protein LC3 exists in two forms (see Figure 1.3), LC3i and LC3ii, 
a phosphatidylethanolamine-conjugated form of LC3-i. LC3-i is widely distributed in the 
cytosol, whereas the conjugated LC3ii form specifically associates with AV membranes 
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(Mizushima et al., 2004). Therefore, we quantified AVs by using LC3 immunolabel in DA 
neurons. Dopaminergic neurons in ventromedial cultures were identified by TH immunolabel. 
Rapamycin strikingly increased LC3-immunolabeled puncta in DA cell bodies and neurites in 
CTL mice but had no effect on puncta in CKOs (p<0.01; ANOVA) (Figures 2.5a-c), showing 
that induction of AVs by rapamycin required Atg7 expression. We observed occasional LC3-
immunolabeled puncta in the Atg7-deficient cell bodies and neurites, possibly due to 
noncanonical AV formation (Nishida et al., 2009). We then examined the induction of LC3ii by 
rapamycin (3 µM) in acute striatal slices by western blotting. Rapamycin at 3.5 hr produced a 
56% increase in LC3ii (Figure 2.5d) (p<0.001; Student’s t-test), but this response was no longer 
apparent at 7 hr, indicating that RAPA induced a transient increase of LC3ii, a feature 
characteristic of macroautophagy.  
 
Having confirmed that macroautophagy was induced in the acute corticostriatal slice, we asked 
whether we could observe degradation of proteins that could explain the effect of rapamycin on 
evoked DA release (see Figures 2.3 and 4). Thus, we examined striatal levels of dopaminergic 
terminal markers DAT and TH, and vesicular markers synaptobrevin and synaptotagmin in wild-
type slices treated with RAPA for 3.5 or 7 hr by western blotting (Figure 2.6). Rapamycin did 
not decrease levels of any of these presynaptic markers. Surprisingly, exposure to rapamycin 
increased levels of TH (Figure 2.6b). PSD95, one of the most abundant components of the 
postsynaptic density was also unaffected by rapamycin (Figure 2.6g). We measured levels of 
PSD95 because changes in this protein have been associated with spine density, which might be 
affected in conditions where there is altered DA release (Comery et al., 1995; Esparza et al., 
2012; Li et al., 2010; Nithianantharajah et al., 2004; Pal and Das, 2013; Toda et al., 2010; Yao et 
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al., 2004). To determine whether this lack of effect was due to 1) macroautophagy not degrading 
these specific proteins, or 2) the 7 hr treatment was insufficient for robust lysosomal degradation 
of autophagosome-delivered components, we examined levels of mitochondrial proteins. A lack 
of reduction in levels of tomm20 and porin suggest that the second hypothesis is more plausible, 
and that 7 hr is not sufficient for macroautophagic degradation. We were unable to extend the 





Figure 2.5 Acute inhibition of mTOR by rapamycin induces a transient induction of 
autophagosome formation in dopaminergic neurons (a.) Cultured dopaminergic neurons 
(TH+) derived from midbrain of wild-type and CTL mice were exposed to rapamycin (3 mM, 3.5 
hr). These exhibited an increased number of LC3+ puncta (green, examples indicated by white 
arrowheads) compared to dopaminergic neurons treated with DMSO. There was no induction of 
LC3+ puncta by rapamycin in DA neurons from CKO mice. Scale bar is 10 µm. (b.) Similar 
results were observed throughout neurites. Rapamycin increased LC3 puncta (white arrows) in 
TH+ neurites, but not in Atg7-deficient dopaminergic neurites. Scale bar is 4 µm. (c.) Number of 
LC3+ puncta per TH+ neuron (cell bodies and neurites) for these conditions (n=3 experimental 
repeats, 30 neurons per experiment per condition; Student’s t-test; **p<0.01). (d.) At 3.5 hr, 
Rapamycin increased LC3ii by 56% (n=3; p<0.001; 2-way ANOVA) but had no effect at 7 hr, 
indicating a temporary induction of LC3ii in the slice preparation consistent with turnover of 






Figure 2.6 Acute mTOR inhibition does not modulate dopaminergic, postsynaptic, or 
mitochondrial protein markers in the striatal slice. Representative western blots of proteins 
from striatal slices obtained from wild-type mice following DMSO or rapamycin (3 µM, 7 hr). 
None of the proteins were significantly decreased by rapamycin at 7 hr exposure. The quantified 




In electron micrographs of striatal slices, we identified AV-like organelles based on previously 
described criteria (Yu et al., 2004) as non-mitochondrial structures in presynaptic terminals that 
possessed multiple membranes, usually with luminal content. These organelles were different 
from multivesicular bodies, organelles of the autophagic-lysosomal pathway that typically 
displays an even distribution of vesicles in the lumen. Many AV-like organelles contained a wide 
range of luminal constituents, including small vesicles resembling synaptic vesicles (compare 
Figures 2.7a and b). Some multilamellar structures were devoid of obvious luminal electron-
dense material (Martinez-Vicente et al., 2010), possibly due to acute induction of AVs by 
rapamycin. It is likely that some of these multilamellar organelles include endosomes or are 
‘‘amphisomes’’ that result from fusion of endosomes and AVs. Rapamycin in the striatal slice 
more than doubled the number of presynaptic terminal profiles containing AV-like structures 
from 15.4% of CTL terminal profiles (n=65) to 35.5% in rapamycin-treated terminals (n=75; 
p<0.05; chi-square test; Figure 2.7c) and decreased terminal profile areas by 19% (p<0.05; 
Student’s t-test; Figure 2.7d). Striatal terminal profiles from rapamycin-treated samples, of 
which only a small fraction are dopaminergic (Gaugler et al., 2012), moreover contained fewer 
synaptic vesicles than untreated controls (49.2 ± 3.6, n=75 vs. 70.1 ± 4.2, n=65; p<0.0001, 




Figure 2.7 Acute mTOR inhibition induces morphological changes at synaptic terminal 
profile (a.-b.) Electron micrographs from untreated corticostriatal slices (a.) and rapamycin-
treated corticostriatal slices (3 µM, 7 hr) (b.). Presynaptic terminal AV-like organelles are 
marked by red arrowheads. Scale bars represent 500 µm. (c.) Rapamycin increased the fraction 
of synaptic terminal profiles with AV-like organelles (p<0.05; chi-square test). (d.) Acute 
rapamycin decreased terminal profile area (p<0.05; Student’s t-test). (e.) Synaptic terminal 
profiles from rapamycin-treated slices contained fewer synaptic vesicles than untreated slices 
(p<0.0001; Student’s t-test). The quantified data are expressed as mean values ± SEM. 
 
 
DA axonal varicosities typically do not display pre- or postsynaptic densities (Nirenberg et al., 
1997 ), but amperometric studies demonstrate stimulation-evoked quantal transmitter release 
from these structures (Pothos et al., 1998), and many accumulate and secrete fluorescent DA 
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analogs (Gubernator et al., 2009), confirming their identity as presynaptic terminals. Because TH 
immunolabel obscured synaptic vesicles and other intracellular structures (see Figure 2.2), we 
examined whether rapamycin reduced the number of dopaminergic synaptic vesicles by using the 
false neurotransmitter 5-OHDA, which is selectively accumulated into these dopaminergic 
synaptic vesicles and produces osmophilic dense cores (Tennyson et al., 1974) (Figure 2.8a-d). 
For each experiment, striatal slices were obtained from a single mouse, bisected, and individual 
striata were incubated in DMSO or rapamycin (3 µM, 6.5 hr) and then treated with 5-OHDA 
(500 µM, 30 min). The numbers of synaptic vesicles in the labeled terminals were compared 
between slices derived from the same mouse. In a wild-type mouse, rapamycin decreased 
synaptic vesicles within 5-OHDA-labeled terminals by 18% (from 105 to 86 synaptic vesicles 
per mm2; p<0.02; Student’s t-test; 37 and 42 terminals rated), and in a CTL mouse, rapamycin 
decreased synaptic vesicles within labeled terminals by 26% (from 82 to 61 synaptic vesicles per 
mm2; p=0.05; Student’s t-test; 31 and 27 terminals rated). In contrast, rapamycin did not 
decrease synaptic vesicles within labeled terminals of a CKO mouse (84 to 95 synaptic vesicles 
per mm2; p=0.13; Student’s t-test; 38 and 39 terminals rated), indicating that rapamycin 






Figure 2.8 Acute mTOR inhibition reduces the amount of synaptic vesicles in dopaminergic 
terminals For each experiment, slices from the same mouse were compared. (a.-b.) Examples of 
synaptic terminals from striatal slices from a wild-type mouse incubated with DMSO for 6.5 hr 
and followed by false neurotransmitter 5-OHDA (500 µM) for 30 min. (c.-d.) Examples of 
terminals in the striatal slice exposed to rapamycin (3 µM, 6.5 hr) and followed by 5-OHDA for 
30 min. Yellow arrows indicate example s of synaptic vesicles in nondopaminergic terminals; 
blue arrows indicate labeled dopaminergic synaptic vesicles; red arrow indicates a structure that 
may be an isolation membrane. Scale bar is 100 nm. (e.-g.) Number of synaptic vesicles per unit 
area (µm2) of 5-OHDA-labeled terminals after exposure to DMSO or rapamycin in wild-type 
(e.), CTL (f.), or CKO (g.) striatal slices. The quantified data are expressed as mean values ± 




We compared the levels of a range of synaptic proteins between striatal slices of CTL mice and 
CKO mice exposed to rapamycin (3 µM) or vehicle for 7 hr. CKO mice showed substantially 
lower levels of DAT, a small but significant decrease of TH (p<0.05; 2-way ANOVA), similar 
levels of the postsynaptic marker PSD95, and the mitochondrial proteins porin, and tomm20 
(Figure 2.9a; Table 2.2.1). Although there was a transient increase in LC3ii at 3.5 hr (see 
Figure 2.5d), no protein examined was altered by rapamycin at 7 hr. This include TH, which 
was significantly increased by rapamycin in wild-type slices. Together, the TH data suggests that 
there might be a difference in protein levels of TH between wild-type and animals containing 
only one copy of DAT. 
 
It may be that although a 7 hr period provided sequestration of cellular elements in AVs, there 
was no measurable net degradation over this period. This data is consistent with what we 
observed in wild-type slices treated with rapamycin (see Figure 2.6). Note that only axons of 





Figure 2.9 Dopaminergic proteins DAT and TH are reduced in DAT-Cre+/-; Atg7fl/fl mice 
Representative western blots of proteins from striatal slices obtained from littermate CTL and 
CKO mice following DMSO or rapamycin (3 µm, 7 hr). Levels of the proteins are displayed in 
Table 1. DAT and TH levels were significantly different between genotypes whereas none of the 
proteins were significantly altered by rapamycin at 7 hr exposure. The quantified data are 





Table 2.1. Average levels of striatal proteins after acute mTOR inhibition in 
macroautophagy-deficient mutants Levels (mean ± SEM, n=3 per condition) of protein 
expression measured by western blotting (see Figure 2.7) following a 7 hr exposure of acute 
striatal slices to DMSO or 3 µM rapamycin. In each experiment, striatal slices obtained from the 
same mouse were exposed to the drugs. Statistics are shown for 2-way ANOVA, with genotype 
(CTL vs. CKO) and treatment (DMSO vs. rapamycin) and interaction between the two factors: 
differences are labeled as p<0.05 or non-significant (n.s.). Note that LC3ii is increased by 




Our data indicate that both basal and induced macroautophagy modulates presynaptic structure 
and function. Mice with chronic macroautophagy deficiency in dopamine neurons had 
abnormally large dopaminergic axonal profiles, released greater levels of neurotransmitter in 
response to stimulation, and exhibited more rapid presynaptic recovery. mTOR inhibition by 
rapamycin administered to control mice induced AV-like structures in axons and decreased 
synaptic vesicles to nearly the same level as the accompanying decrease in evoked dopamine 
release. In contrast, rapamycin had little or no effect on the number of synaptic vesicles or 
neurotransmitter release in macroautophagy-deficient neurons. Together, our results introduce 
acute presynaptic changes that depend on Atg7 expression and hence macroautophagy.  
 
These presynaptic effects were observed in dopaminergic presynaptic terminals in slices without 
their cell bodies, and so the critical steps in autophagy must have occurred locally in axons that 
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typically lack mature lysosomes (Overly et al., 1995). Our data confirm that AVs can be 
synthesized locally in the axons (Lee et al., 2011) and indicate that local axonal autophagy can 
sequester presynaptic components and modulate presynaptic function. This evidence extends 
studies of selective degradation of postsynaptic receptors via macroautophagy (Hanley, 2010; 
Matsuda et al., 2008; Rowland et al., 2006) and classic work indicating a role for lysosomal 
degradation in recycling synaptic vesicle turnover (Holtzman et al., 1971). Thus, in addition to 
well-established roles of macroautophagy in stress response and cellular homeostasis (Tooze and 
Schiavo, 2008), neurons have adapted this phylogenetically ancient process to modulate 
neurotransmitter release and remodel synapses.  
 
Chronic macropautophagy deficiency and neuronal morphology 
Macroautophagy deficiency throughout the CNS results in decreased weight, motor deficits, and 
premature death (Hara et al., 2006; Komatsu et al., 2006). Purkinje cells from cell-specific 
autophagy-deficient mice show axonal swellings and signs of neurodegeneration as early as 
postnatal day 19 (Komatsu et al., 2007a). Signs of neurodegeneration were, however, not 
observed in young CKO (<14 weeks), possibly due to compensation by other degradative 
pathways (Koga et al., 2011). It may be that further aged CKO mice model aspects of 
Parkinson’s-related disorders. Indeed, an independent study showed that, similar to other models 
conditionally lacking Atg7, these animals demonstrate an age-dependent loss of dopaminergic 
neurons (Ahmed et al., 2012; Inuoe et al., 2013). 
 
Chronic autophagy deficiency rather increased the size of dopaminergic synaptic terminal 
profiles and striatal dopaminergic innervation, consistent with studies that implicate 
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macroautophagy in retraction of neuronal processes (Bunge, 1973) and neuritic growth in 
developing neurons (Hollenbeck, 1993). The results, however, contrast with studies in 
Drosophila, in which disruption of AV formation or AV-lysosomal fusion decreases the size of 
the neuromuscular junction, whereas Atg1 overexpression or rapamycin promotes 
macroautophagy and increases the number of synaptic boutons and neuritic branches (Shen and 
Ganetzky, 2009). Some synaptic Atg1-related changes may be autophagy independent because 
the loss of other autophagy-related proteins does not mimic the effect of Atg1 overexpression on 
the number of boutons and neurite branches (Toda et al., 2008; Wairkar et al., 2009).  
 
We further observed that chronic Atg7 deficiency in dopaminergic terminals led to an increase in 
presynaptic number of mitochondria (data not shown); Atg7 deficiency may contribute to 
changes in mitochondria in multiple ways, for example, via effects on presynaptic mitochondria 
size, shape, trafficking, fission, and fusion. 
 
Autophagy induction and synaptic vesicles 
Acute induction of AVs by rapamycin in control neurons was confirmed by electron microscopy, 
LC3 immunolabel, and transiently elevated protein levels of LC3ii. Acute exposure to RAPA 
decreased synaptic terminal profile size and number of synaptic vesicles, indicating that mTOR 
inhibition can rapidly decrease presynaptic components. Some AV-like profiles contained cargo 
that resembled synaptic vesicles, although we were unable to immunolabel AV components, 
presumably due to the low luminal pH. Presynaptic terminals are very active in endocytosis due 
to the turnover and recycling of synaptic vesicles, receptors, and other constituents, and it is 
likely that many of the multilamellar organelles we observe are products of the fusion of 
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endosomes and AVs, sometimes called ‘‘amphisomes’’. An apparently clear content of 
occasional AV-like organelles suggests that acute mTOR blockade may result in some ‘‘empty’’ 
early AVs (Martinez-Vicente et al., 2010). AV-like profiles were absent in dopaminergic axon 
profiles of the Atg7-deficient mice, and although low levels of LC3-immunolabeled puncta were 
present in the mutant neurons, they were not enhanced by rapamycin. Thus, the increase in AVs 
by mTOR inhibition apparently requires Atg7, and we hypothesize that, in normal neurons, 
rapamycin redistributed synaptic vesicle membranes into axonal AVs, endosomes, and/or 
amphisomes. 
 
Synaptic transmission in DAT-Cre+/-; Atg7fl/fl animals 
Chronic lack of macroautophagy enhanced evoked DA release and the rate of synaptic recovery. 
At a variety of synapses, a higher release probability can increase the peak amplitude from the 
first pulse followed by a relative depression from the second pulse, due to a decreased 
availability of release-ready vesicles, culminating in a lower paired-pulse ratio (second pulse/first 
pulse). This situation differs from that in CKO animals, in which both the initial and subsequent 
pulses showed increased amplitudes relative to CTL mice. The probability of dopaminergic 
synaptic vesicle fusion is regulated by the size of the recycling and readily releasable pools 
(Daniel et al., 2009): the enhanced release and recovery in the mutant line could be due to 
multiple nonexclusive effects, including a greater synaptic terminal size or density, a greater 
number of synaptic vesicles, more calcium influx, or an increase in vesicle docking and fusion 
sites and/or rates. We measured lower total striatal DAT and TH levels in the macroautophagy-
deficient line, although the kinetics of DA release do not indicate altered activity of the proteins, 




Rapamycin depressed evoked DA release in control mice but had no effect in CKO mice, 
confirming that the rapid changes in neurotransmission evoked by mTOR inhibtion were 
macroautophagy dependent and not the result of effects on protein synthesis. 
 
Although we have focused on dopaminergic terminals, the data suggest that these effects are not 
specific to them. Rapamycin induced apparent AVs in both dopaminergic (TH+) and 
nondopaminergic (TH-) terminals, and a decrease in synaptic vesicles was observed generally in 
striatal synaptic terminals, which include glutamatergic, dopaminergic, GABAergic, and 
cholinergic synaptic terminals. Our experiments do not address how subsets of particular 
presynaptic organelles, such as individual synaptic vesicles, may be specifically targeted by 
mTOR-dependent axonal macroautophagy. Clues might be offered if alternative modes of 
vesicle recycling are identified that could partake in or avoid endocytic compartments that might 
fuse with AVs (Voglmaier et al., 2006).  
 
Starvation, injury, oxidative stress, toxins, including high doses of methamphetamine, and 
infection by neurotropic viruses trigger autophagy in neurons, which is further associated with 
protein aggregate-related disorders, including Huntington’s, Parkinson’s, and Alzheimer’s 
diseases (Cheng et al., 2011; Koga et al., 2011; Larsen et al., 2002a; Talloczy et al., 2002; Tooze 
and Schiavo, 2008). mTOR activity is regulated by multiple endogenous pathways involved in 
synaptic activity and stress, including tuberous sclerosis complex, ras homolog enriched in brain 
(Rheb), protein kinase B (AKT), neurofibronin, and phosphate and tensin homolog (PTEN) 
(Malagelada et al., 2010). Alterations in mTOR activity are associated with neuropathological 
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conditions such as epilepsy, tuberous sclerosis, and autism. Regulation of presynaptic function 






















Macroautophagy and the corticostriatal synapse 
 
INTRODUCTION 
Cell homeostasis, including in neurons, is maintained by an interplay between production 
(transcription and translation) and elimination (degradation and recycling) of proteins. This 
balance is required for proper function, from individual synapses to that of whole-animal 
behavior. Not surprisingly, the process of protein elimination is tightly controlled and results in 
the protein being degraded by either the proteasome or the lysosome, the organelle ultimately 
responsible for the degradation of cytosolic components sequestered by macroautophagy. While 
the role of the ubiquitin-proteasome system in neuroplasticity has been studied extensively, how 
macroautophagy specifically affects different types of plasticity remains relatively unexplored 
(Bingol & Sheng, 2011).  
 
The process of macroautophagy is regulated by mTOR, a kinase that suppresses macroautophagy 
via phosphorylation of Atg13. When unphosphorylated, Atg13 induces a cascade of reactions, 
later involving Atg7, which leads to autophagosome formation, and therefore macroautophagy 
(Kamada et al., 2010). mTOR also promotes cell growth and proliferation via upregulation of 
protein synthesis by phosphorylating ribosomal subunit S6 kinase (p70S6K) (Huang & Manning, 
2009). Owing to its multiple functions, while the mTOR signaling pathway has been shown to be 
essential to many forms of plasticity. These data stems mainly from studies in which the mTOR 
inhibitor rapamycin was used. Interestingly, the involvement of mTOR activity are usually 




Macroautophagy was first described as a response to starvation, a phenomenon against which the 
brain seemed protected (Mizushima et al., 2004). It was not until animal models lacking specific 
components of the macroautophagic machinery became available that the significance of this 
process in the brain could be understood. By genetically removing Atg7 or Atg5 function from 
the brain, it was shown that basal levels of macroautophagy are protective against formation of 
inclusion bodies (large aggregates of undegraded protein), neurodegeneration and decreased 
survival of mutant mice (Ahmed et al., 2012; Inoue et al., 2013; Komatsu et al., 2006; Komatsu 
et al., 2007a). Mutants also display behavioral phenotypes when tested for locomotion, motor 
coordination and the limb-clasping reflex. This indicates that the total absence of 
macroautophagy in the brain is sufficient to lead to some of the motor symptoms reminiscent of 
hose observed in patients with neurodegenerative disease.  
 
In an effort to uncover a role for macroautophagy in other basal ganglia populations, we 
generated a mouse line lacking Atg7 in D1R+ neurons. Accumulation of p62 has been used 
previously to confirm lack of macroautophagy in mouse lines lacking genes involved in this 
process, including Atg7 (Waguri and Komatsu, 2009). We took advantage of this method in 
conjunction with immunofluorescent colabeling to confirm the lack of macroautophagy in D1R+ 
neurons in the striatum. We also hypothesized that these mice would have significantly more 
spines in D1R+ medium spiny neurons due to an impaired ability to degrade spine components. 




Spines are small dendritic protrusions and serve as substrates for many forms of neuroplasticity 
(Colgan and Yasuda, 2013). Mature spines contain PSDs, an electron-dense membrane 
specialization that enables the spine to receive and process information (Gray, 1959; Kim and 
Sheng, 2009). Many proteins come together to form the PSD (reviewed in Boeckers, 2006). 
Scaffold proteins link neurotransmitter receptors embedded in the membrane to intracellular 
messengers, transforming the PSD into a highly organized functional signaling complex. 
Members of the membrane-associated guanylyl kinase (MAGUK) family are among the scaffold 
proteins closest to the synapse. The most abundant family member in the rat forebrain is PSD95 
(Nagura et al., 2012), which is also the best-characterized member of the MAGUK family. It is 
well established that PSD95 interacts with both AMPA and NMDA receptors, regulating their 
localization and function (reviewed in Xu, 2011). 
 
PSD95 is among the earliest proteins to cluster at spines during synapse formation (Okabe et al., 
2001; Rao et al., 1998). Indeed, the appearance of PSD95 at spines coincides with stabilization 
of previously transient dendritic structures (De Roo et al., 2008). Importantly, overexpression of 
PSD95 in hippocampal cultures increases synaptic clustering of GluR1 (an AMPA receptor 
subunit), and GKAP (a PSD95-interacting scaffold protein), accompanied by greater mEPSC 
amplitudes (El-Husseini et al., 2000). This manipulation also resulted in an enlargement of 
spines, and in an overall increase in spine density in both pyramidal and interneuron 
hippocampal populations. Finally, PSD95 content is correlated to PSD and spine size (Aoki et 
al., 2001; Harris and Stevens, 1989). Such evidence is in accord with data showing a reduction in 




Given the critical role of PSD95 in synapse formation and maintenance, it seems highly probable 
that experiences that modify overall levels of PSD95 could alter spine density, and vice versa. In 
support of this statement, environmental enrichment, which consists in housing animals socially 
and in cage filled with interactive objects (i.e. running wheel, climbing ladder, ball, and nesting 
material) leads to an increase in PSD95 levels (Nithianantharajah et al., 2004). Comery et al. 
(1995) used a similar method to those show that induce increases in spine density in the striatum. 
Furthermore, a single systemic injection of ketamine increases protein levels of PSD95 with a 
time course that parallels that of transient spine density increases (Li et al., 2010). On the other 
hand, it appears that when spine density and levels of PSD95 are assessed in the same study, 
psychostimulant treatments that fail to affect PSD95 also fail to modulate spine density or 
synapse number as assessed by electron microscopy (Esparza et al., 2012; Toda et al., 2010; Yao 
et al., 2004). A similar correlation is observed after morphine administration (Pal and Das, 
2013). These data support the connection between protein levels of PSD95 and spine density.  
 
Here we used mice confirmed to be D1R+ macroautophagy deficient as demonstrated by the 
accumulation of p62+ aggregates, a known substrate of macroautophagy, in neurons colabeled 
with 1) Cre recombinase and 2) markers of direct pathway medium spiny neurons. Formation of 
these aggregates was observed to be age-dependent, first appearing in the dorsal and then the 
ventral striatum. We hypothesized that lack of macroautophagy would result in neuronal loss and 
motor pathway-specific behavioral phenotypes, such as limb-clasping. Although limb-clasping 
was not impacted, preliminary data suggests early signs of neurodegeneration as shown by 
astrogliosis and cellular condensation. Thus, it is possible that more sensitive behavioral assays 
might be able to detect subtler changes in motor performance. In addition, we found that 1) 
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PSD95 levels in the striatum are not different in macroautophagy-deficient animals, 2) a chronic 
treatment with rapamycin, did not alter PSD95 levels. Additional preliminary data also suggests 
that mutants might exhibit changes in presynaptic dopaminergic neurotransmission. In 
conclusion, our mutants underscores the importance of macroautophagy in the striatum.  
 
METHODS 
Animals. D1R-Cre+/-; ATG7fl/fl; (CKO) mice were generated by flanking exon 14 of the ATG7 
gene with loxP sites (Komatsu et al., 2005) and mating the ATG7fl/fl  line with mice carrying Cre 
recombinase under the control of the D1R promoter (Gong et al., 2007) so that expression is in 
the striatum, restricted to direct pathway medium spiny neurons. Animals were crossbred into 
C57BL/6 mice for a minimum of 9 generations. C57BL/6 male mice aged 8-10 weeks were 
purchase from Jackson Labs (Bar Harbor, ME). Mice were housed in groups of 2-5 in a 12:12 hr 
light-dark cycle and given access to food and water ad libitum. All procedures were approved by, 
and performed in accordance with the Institutional Animal Care and Use Committee at Columbia 
University.  
 
Immunofluorescence. Male and female mice (3-8 months of age) were anesthetized with 
ketamine/xylazine (100 mg/kg and 10 mg/kg respectively) and a needle connected to a perfusion 
pump was inserted into the left ventricle. A 1X PBS solution containing heparin (1 unit/ml; 
195.9 units/mg) was transcardially perfused at 3.75 ml/min for 3 min to wash out the blood. This 
was followed by 4% paraformaldehyde (3.75 ml/min) for 5 min. The fixed brain was then 
removed from the skull and incubated in 4% paraformaldehyde overnight followed by 2-3 days 
in 30% sucrose in 0.1M phosphate buffer (PB) at 4°C. Floating sections (30 µm) containing 
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striatal tissue were collected into 1X PBS using an open-air freezing microtome, washed twice in 
1X PBS, and blocked (0.03% TritonX100-1X PBS, 10% NDS) for 1 hr. Antibodies used were 
anti-guinea pig p62 (American Research Products), anti-rabbit DARPP32 (Cell Signaling) and 
anti-rabbit substance P (Peninsula Labs) in 0.03% TritonX100-1X PBS, 2% NDS overnight at 
4°C. After 3 washes in 1X PBS, sections were exposed to species-specific secondary antibodies 
(Novus Biologicals or Jackson Immunoresearch Laboratories), and re-washed in 1X PBS.  
Sections were finally mounted on glass unsubbed microscope slides and coverslipped in 
fluoromount (Sigma). 
 
Confocal microscopy. Images were obtained with a Leica SP5 confocal microscope equipped 
with the appropriate lasers and filters sets. The number of LC3+ puncta in the soma and neurites 
was quantified using Image J software. 
 
Striatal protein collection. Mice were sacrificed by cervical dislocation, total striatum was 
excised in cold 1X PBS, and transferred to an Eppendorf containing lysis buffer [EDTA-free 
protease inhibitor mixture (1 tablet/10 ml; Roche), phosphatase inhibitor cocktail 2 (1:100; 
Sigma) in RIPA buffer (Sigma)] and stored at -20°C. Striatal tissue was sonicated on ice with a 
dismembrator, centrifuged at 14 krpm for 10 min, and the pellet was discarded, followed by 
boiling of the supernatant at 100°C for 5 min. Protein concentration was determined by the BCA 
(Pierce, Brebieres, France) method. Protein was then mixed with 4X loading buffer (40% 
glycerol, 8% SDS, 20% β-mercaptoethanol, 0.1% bromophenol blue, 250 mM Tris base, pH 




Western blot. A total of 25 µg (based on linear range experiment; see Figure 4.1 in Chapter 4) 
of total protein in loading buffer was boiled at 100°C for 5 min and loaded in each well of a 10% 
bisacrylamide (Biorad) gel and run at 180-200 mV for 1 hr or until the protein ladder markers 
(Fisher) were well separated. Protein was transferred to a methanol-activated PVDF (Millipore) 
membrane at 40 mV for 3 hr or at 10 mV overnight. Membranes were then rinsed and washed 
once in 1X TBS/0.05% Tween-20, blocked in 5% milk and incubated with the following primary 
antibodies: 1:60000 anti-mouse beta-actin (Sigma), 1:1000 anti-rabbit PSD95 (Abcam) and anti-
rabbit Homer1b/c (Santa Cruz). Blots were washed, incubated for 30 min with goat HRP-
conjugated anti-mouse or anti-rabbit (Thermoscientific) secondary antibodies at a concentration 
of 1:10000, and re-washed. Protein bands were detected by chemiluminescence (Millipore) and 
quantified by densiometry (Image J). Data on figures is presented as mean ± SEM, and specific 
statistical tests used are indicated in figure legends.  
 
Limb-clasping test. Mice were suspended in the air by their tails for 12 s the clasping of their 
hind legs was evaluated. Animals displaying standard escape response were given a score of zero 
whereas animals that maintained legs in clasped or dystonic position were given a score of one. 
Data were compared using a Student’s t-test.   
 
RESULTS 
D1R-Cre+/-; Atg7fl/fl mice are confirmed direct pathway macroautophagy conditional 
knockouts 
D1R-Cre+/-; Atg7fl/fl (CKO) mice were assessed for lack of macroautophagy in D1R-rich brain 
regions by staining with an antibody against p62. Accumulation of p62+ aggregates has been 
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used previously to confirm lack of macroautophagy in mouse lines lacking genes involved in this 
process, including Atg7 (Waguri and Komatsu, 2009). Aggregates positive for p62 were 
observed in cell bodies and neurites in the dorsal striatum (Figure 3.1a), deep layers of the 




Figure 3.1 P62 aggregates confirm lack of functional macroautophagy in D1R-rich regions 
in D1R-Cre+/-;ATG7fl/fl mice Images of p62-labeled sagittal floating sections of dorsal striatum 
(a.), cortex (b.), and olfactory bulb (c.) from 3-month D1R-cre+/-; ATG7+/+ (CTL) (a.-c.), and 
D1R-Cre+/; ATG7fl/fl (CKO) (a’.-c’.) by immunofluorescence. Note how p62+ neurons are 
present only in CKO animals, and only in cell bodies and neurites of D1R-rich regions. 
 
 
In order to confirm that the aggregates seen in the dorsal striatum were in direct pathway D1R+ 
medium spiny neurons, we co-immunolabeled sagittal slices with p62 and DA and cAMP-
regulated phosphoprotein, MW 32 kDa  (DARPP32) (Figure 3.2a), or substance P (Figure 3.2b) 
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(Anderson and Reiner, 1991; Langley et al., 1997). Images showed that all p62+ neurons were 
also positive for DARPP32 and substance P. This indicates that neurons lacking Atg7 are in fact 
direct pathway medium spiny neurons. 
 
 
Figure 3.2 ATG7flox/flox ; D1R-Cre+/- CKO mice are confirmed as direct pathway medium 
spiny neurons Z-stack images of p62 co-immunolabeled with DARPP32 (a.-a’.) or substance P 
(b.-b’.) from sagittal floating sections of dorsal striatum from 3-month D1R-Cre+/- ; ATG7fl/fl 
(CTL) (a. and b.), and D1R-Cre+/; ATG7fl/fl (CKO) (a’. and b’.). Note that p62+ neurons express 
both DARPP32 and Substance P. Scale bar is 30 (a.) and 50 µm (b.). 
 
 
D1R-Cre+/-; Atg7fl/fl mice exhibit spatiotemporal variations in p62 accumulation 
Marked differences in the presence of p62+ aggregates were noted when comparing different 
ages, or striatal subregions. In dorsal striatum, robust accumulation of p62 only occurs between 1 
(4.4 ± 2.3) to 3 (13.9 ± 2.7) months of age, suggesting that p62 aggregation requires weeks to 
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months to develop after the initial recombination event (Figure 3.3a). Although, p62+ aggregates 
are also abundant at 8 months (12.9 ± 1.8), their number is not significantly higher than at 1 
month. This suggests that the numbers of p62+ neurons might be declining from 3 to 8 months. 
 
 
Figure 3.3 P62 aggregates accumulate age-dependently in the adult dorsal striatum (a.) Z-
stack images of p62-labeled sagittal floating slices of dorsal striatum from 1, 3 and 8-month 
D1R-Cre+/-; ATG7fl/fl (CTL) and CKO by immunofluorescence were analyzed for number of 
p62+ cell bodies in an area of 65,000 mm2 (15 areas per animal; n=3-4 animals per group). Note 
that the density of p62+ neurons rises significantly between 1 and 3 months of age in the dorsal 
striatum of CKOs, but there is no significant difference between 3 and 8 months of age. Scale bar 
is 50 µm. (b.) Quantification of p62+ neurons in dorsal striatum 1 and 3 month CTL and CKOs. 
The quantified data are expressed as mean values ± SEM and were analyzed by Student’s t-test. 
**p<0.01. (c.) Quantification of p62+ neurons in dorsal striatum 1, 3 and 8 month CKOs. The 
quantified data are expressed as mean values ± SEM and were analyzed by 1-way ANOVA 
followed by a Dunnett’s test using 1 month CKOs as controls. *p<0.05.  
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To determine whether these differences are due to D1R-Cre recombinase’s onset of expression 
being different or due to CKO (D1R-Cre+/-; Atg7fl/fl) neuron cell death has been explored by 
several methods. While there seems to be less intense immunofluorescent label of p62 when 
comparing 3 versus 8 months, quantification in the dorsal striatum did not reveal a significant 
difference in the number of p62+ neurons at these ages. Also, the number of p62+ neurons is 
significantly higher at 3, but not 8 months, when comparing them to numbers obtained from 8 
month CKOs (Figure 3.3c). However, visual inspection of p62+ neurons at these ages revealed 
that 8-month cells appeared smaller (Figure 3.4a). Quantitative analysis shows that p62+ neuron 
diameter at 8 months is significantly smaller (11.1 ± 0.2 nm; n=38) than at 3 months (13.6 ± 0.3 
nm; n=42) (Figures 3.4b). This cell shrinkage could be indicative of impending apoptosis of 
p62+ neurons and future neurodegeneration (Bortner and Cidlowski, 2002). However, as we used 
the p62 to delineate the cell, and this signal is only present in CKOs, we are do not know if this 
reduction in size is due to chronic lack of Atg7, or caused by aging. To differentiate between 






Figure 3.4 Comparison of 3 and 8 month macroautophagy conditional knockouts reveal 
signs of cellular condensation (a.) Z-stack images of p62-labeled sagittal floating slices of 
dorsal striatum from 3 and 8-month D1R-Cre+/-; ATG7fl/fl (CTL) and CKO by 
immunofluorescence were analyzed for p62+ cell diameter. Scale bar is 50 (left) and 10 µm (right 
panel). (b.) Substance P/p62+ neuron diameter, an indication of was significantly decreased in 8 
month versus 3 month CKOs (n~40 cells). The quantified data are expressed as mean values ± 
SEM percent of 3 month CKO animals and were quantified by Student’s t-test. 
 
 
Analysis of Cre staining by immunofluorescence showed that Cre recombinase is expressed as 
early as 1 month in the dorsal striatum in both CKOs and CTL mice (D1R-Cre+/-; Atg7fl/fl), 
suggesting that the absence of a large number of p62+ cell bodies at 1 month is not due to failure 
of Cre-mediated recombination in D1R+ neurons (Figure 3.5). This suggests that following the 
disappearance of Atg7 function, accumulation of p62+ aggregates is not immediate, but requires 




Figure 3.5 Spatiotemporal analysis of Cre recombinase staining in dorsal and ventral 
striatum in D1R-Cre+/-; ATG7fl/fl CKO mice (a.-b.) Z-stack images of Cre/p62-labeled sagittal 
floating slices of dorsal and ventral striatum from 1, 3 and 8 month D1R-Cre+/-; ATG7+/+ (CTL) 
and D1R-Cre+/; ATG7fl/fl (CKO). (a.) Note how in the dorsal striatum, Cre is present at all tested 
ages. Also, all p62+ neurons are Cre+. (b.) In the ventral striatum, Cre is absent at all ages, except 





In terms of differences between the dorsal and ventral striatum, results indicate that D1R-Cre+/ 
mice do not begin to express significant amounts of Cre (and therefore p62+ neurons) in the 
ventral striatum until around 8 months of age. The spatiotemporal pattern of striatal p62+ staining 
in CKOs can be appreciated anatomically in Figure 3.6. 
 
 
Figure 3.6 Spatiotemporal analysis of p62 staining in striatum in D1R-Cre+/-; ATG7fl/fl 
CKO mice Images of p62-labeled sagittal floating slices of entire striatum from 1, 3 and 8 
month D1R-Cre+/; ATG7fl/fl (CKO) were used to reconstruct the entire striatum. Note the how 
p62 labeling is strongest at 3 months in the dorsal striatum, but at 8 months in ventral striatum. 
Dashed lines are encircling the anterior commissure, and used as an anatomical landmark to 
compare striata at the same depth. 
 
 
Finally, in an effort to investigate signs of cell stress that could precede neurodegeneration, I 
compared patterns of glial fibrillary acidic protein (GFAP) staining in 3 month CTL and CKO 
animals by immunofluorescence. Colabeling with antibodies against DAT shows that two out of 
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three CKOs analyzed exhibit denser GFAP staining (Figure 3.7); a characteristic indication of 
astrogliosis. Interestingly, levels of DAT staining appears significantly higher in all 3-month 
CKO animals tested when compared with age-matched CTLs. This data, together with the 
decrement in p62+ cell body diameter, features that might predict current and later basal ganglia 
dysfunction, suggests that the lack of basal macroautophagy in D1R+ medium spiny neurons 
compromises normal striatal tissue health, and possibly neurotransmission.   
 
 
Figure 3.7 Higher levels of GFAP and DAT in CKO young adults Z-stack images of 
DAT/GFAP-immunolabeled sagittal floating slices of dorsal striatum from D1R-Cre+/-; ATG7+/+ 
(CTL) and D1R-Cre+/; ATG7fl/fl (CKO) mice. Note how immunolabel for GFAP and DAT is 






Chronic rapamycin treatment fails to regulate PSD95 & Homer1b/c 
As discussed in the introduction, effects following modulation of mTOR can be due to changes 
in protein translation, macroautophagy, or both. To determine whether modulation of mTOR 
activity can affect overall striatal protein levels of PSD95 and Homer1b/c, mice were injected 
with DMSO or rapamycin. We used a regimen previously shown to decrease phosphorylation of 
p70S6K and increase in LC3ii, two measures of low mTOR activity (Figure 3.8).  
 
 
Figure 3.8 A chronic rapamycin regimen efficiently blocks mTOR activity Striatal 
homogenates were collected and analyzed for levels of P-p70S6K, total p70S6K, and LC3. 
Animals were injected for 7d with DMSO (1 µl/g) or rapamycin (2 ml/kg). Note that 
phosphorylation of p70S6K are significantly lower, and LC3ii levels are increased in RAPA-
treated animals. The quantified data are expressed as mean values ± SEM. 
 
 
Having confirmed appropriate mTOR inhibition by RAPA, we used this regimen to examine 
whether mTOR can affect PSD components, specifically dendritic spine scaffold proteins PSD95 
and Homer1b/c. We found that rapamycin did not significantly modulate PSD95 or Homer1b/c 
in striatum of wild-type animals (Figure 3.9a). To evaluate the specific role of macroautophagy, 
we also evaluated levels of these 2 proteins in CKOs. No significant difference was found 
between CKO and CTL animals (Figure 3.9b). However a trend (p=0.15) towards increase in 
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PSD95 (CTL: 96.7 ± 10.2; CKO: 125.9 ± 18.6), but not in Homer1b/c levels was observed. We 
are currently collecting striatal tissue homogenates from additional animals to determine whether 
this trend is substantive. 
 
 
Figure 3.9 Effects on mTOR modulation and lack of macroautophagy on levels of striatal 
PSD95 and Homer1b/c (a.-b.) Striatal homogenates were collected and analyzed for levels of 
postsynaptic proteins PSD95 and Homer1b/c. (a.) Animals were injected for 7d with DMSO (1 
µl/g) or rapamycin (2 ml/kg). There was no significant difference (n~9) in levels of either protein 
when comparing vehicle-injected with rapamycin-injected animals, or when comparing basal 
levels in D1R-Cre+/-; ATG7fl/fl (CTL) and CKOs. (b.) The quantified data are expressed as mean 





This trend led us to look directly at the PSD by electron microscopy. We found that the area of 
PSDs in the dorsal striatum was significantly increased in 2 month old CKOs (13,556 ± 350 nm2; 
n=726), when compared to age-matched controls (11,072 ± 186 nm2; n=971; Figure 3.10a and 
b). We also examined the number of PSDs per area. We did not find a significant difference 
between CTLs and CKOs and this age. Incidentally, we noticed numerous mitochondria swollen 
by what seemed to be liquid-filled spaces in mutant slices of dorsal striatum. Thus, we quantified 
these organelles, and found that a significantly larger proportion of mitochondria show this 
phenotype in CKO (45.6 ± 2.2 %) when compared to CTL (14.9 ± 0.8 %) animals (Figure 3.10c 
and d). We did not observe such an obvious effect in mice that lacked macroautophagy in 
dopaminergic neurons (Daniela Hernandez, personal communication), which suggests that 
mitochondria might be especially sensitive in medium spiny neurons and that this vulnerability 







Figure 3.10 D1R-Cre+/-; ATG7fl/fl CKO mice contain larger PSDs and a higher proportion 
of damaged mitochondria Slices of dorsal striatum from 2 month old CTL and D1R-Cre+/; 
ATG7fl/fl (CKO) were processed to obtain electron micrographs (n=40 per group) with an area of 
180 µm2. (a.-b.) CKOs exhibit a small but significant PSD size increase. There was no difference 
between the number of PSDs per area between CTL and CKOs in the dorsal striatum. The 
quantified data (n~850) are expressed as mean values ± SEM and were analyzed by a Mann-
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Whitney test. (c.-d.) The proportion of damaged (swollen) to normal-appearing mitochondria is 
significantly larger in CKOs. Mitochondria were scored as damaged if they contained large areas 
devoid of cristae, or had ruptured membranes. Note that at this age, the number of mitochondria 
per area is not affected in mutant mice. The quantified data (n~44) are expressed as mean values 
± SEM and were analyzed by Student’s t-test. (e.) Representative electron microscopy images 
from CTL and CKO mice. Arrows indicate examples of PSDs. Black and yellow asterisks are 




Rapamycin is the drug most commonly used to study the mTOR pathway. Effects of the widely-
used drug rapamycin could be due to inhibition of protein synthesis, induction of 
macroautophagy, or both. We developed a conditional knockout mouse line where the ability to 
undergo macroautophagy (Atg7fl/fl) is absent from one of the major neurons in the striatum; the 
D1R+ medium spiny neuron. We successfully used this strategy previously to explore the role of 
macroautophagy in dopaminergic neurons. Mutant mice were born at a normal ratio, indicating 
that they develop normally. By detecting the aggregation of p62 we show that mice did lack the 
ability to degrade cytosolic components through a mechanism dependent on Atg7. This protein is 
a well-known substrate of macroautophagy (Bjorkoy et al., 2005; Yue, 2007) and is commonly 
used to confirm the absence of functional macroautophagy (Waguri and Komatsu, 2009). 
Although accumulation of p62 could arise through an increase in the rate of transcription of this 
gene, changes in p62 mRNA have not been assessed in mouse models where macroautophagy 
function is selectively removed from neuronal populations. However, Komatsu et al. (2007b) 
reported that removing Atg7 in liver hepatocytes did not increase p62 mRNA, as determined by 
reverse transcriptase (RT)-PCR. In addition, similar findings have been reported in Atg4b KO 
animals, another autophagy related protein whose absence in cells results in accumulation of 
p62+ aggregates (Mariño et al., 2010). These studies suggest that accumulation of p62+ 
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aggregates in cells with disturbances in, or lack of macroautophagy is mainly due to a decrease 
in protein turnover, and not transcriptional regulation of p62. Thus, we were confident that 
presence of p62+ aggregates can be used to confirm the functional absence of macroautophagy in 
Atg7-deficient D1R+ medium spiny neurons. 
 
We found that p62 aggregates were present solely in neuronal cell bodies of D1R-rich regions; 
the striatum, the prefrontal cortex, and the olfactory bulb. Of note, expression is mostly dorsal, 
although the number of p62+ medium spiny neurons seems to increase in the ventral striatum at 
later ages. Finally we confirmed that, as expected, p62+ aggregates in the striatum were restricted 
to direct pathway medium spiny neurons (substance P+/DARPP32+).  
 
Preliminary data suggests early signs of neuronal health decline. First, an increased presence 
GFAP-immunolabeled astrocytes was observed in the dorsal striatum as early as 3 months. 
Secondly, neuron diameter was decreased from 3 to 8 months in CKO animals. However, 
because p62 signal, which is absent in CTLs, was used to estimate this measure, we cannot 
confirm that this is due to lack of macroautophagy or to aging. Lastly, 2 month old mice 
exhibited a large proportion of abnormal mitochondria. More detailed studies are required to 
explore the neurodegenerative potential in this mouse line. 
 
mTOR, macroautophagy and the postsynaptic density 
Our data on dendritic spine scaffold proteins in 3 month old macroautophagy-deficient mice 
showed a trend towards increase in striatal levels of PSD95. If lack of macroautophagy indeed 
leads to an increase in PSD95, an observable increment might be masked by the overwhelming 
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presence of D2R+ medium spiny neurons in striatal homogenates. An alternate plausible 
explanation is that the marked difference between the dorsal and ventral striatum, in terms of Cre 
expression (see Figure 3.6), is occluding a possible difference in levels of PSD95 in the dorsal 
striatum of CKO mice. This hypothesis could be tested by assessing PSD95 in different striatal 
regions separately.  
 
To determine whether chronic mTOR modulation could modify PSD95 in wild-type animals, we 
used a 7 day (single daily injection) rapamycin treatment. We show that this treatment inhibits 
mTOR activity and increases autophagosome formation, as assessed by levels of P-P70S6k and 
LC3ii by western blot. Levels of PSD95 were unaffected by this regimen. Striatal homogenates 
were collected ~18 hr following the last injection of DMSO or rapamycin. If PSD95 levels were 
changed by mTOR inhibition, it is possible that this time point might not be ideal to detect a 
significant difference. In addition, PSD95 is translated in an mTOR-dependent which could lead 
to an additive effect on the amount of PSD95 in the striatum (Lee et al., 2005). This supports the 
hypothesis that by looking at a single time point, we might have missed the expression of a 
significant reduction in PSD95.  
 
In contrast, we observed that lack of macroautophagy in D1R+ medium spiny neurons lead to a 
significant increase in the size of PSDs in the dorsal striatum. mTOR has been implicated in 
many forms of synaptic plasticity (Jaworski and Sheng, 2006). To our knowledge, however, this 
is the first study to report a direct role for macroautophagy in controlling PSD size. At 2 months, 
mutant mice had larger PSDs than CTL animals. Due to our methods not being able to 
distinguish between D1 or D2R+ medium spiny neurons, the data analyzed includes PSDs that 
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belong to both types of cells. Assuming that this effect stems from changes occurring in D1R+ 
medium spiny neurons, this suggests that our analysis is probably an underestimation of the size 
of the PSD in these neurons in macroautophagy-deficient animals.  
 
PSD and spine size is correlated to PSD95 content, which might explain why we found a trend 
towards increase in total striatal levels of PSD95 in macroautophagy-deficient mice (Aoki et al., 
2001; Harris and Stevens, 1989). It remains to be determined exactly how macroautophagy can 
affect PSD size, and PSD95 in particular. One possibility could involve dendritic 
autophagosomes that get close enough to spines, and then non-selectively engulf proteins that 
have temporarily left the PSD due to a particular certain stimulus. A second possibility involves 
stimuli-dependent endocytosis at the spine, with PSD95 and other PSD proteins tagging along 
with the internalized receptor, and later fusion of this endosome with an autophagosome. As our 
data suggests an important role for macroautophagy in synaptic strength and postsynaptic 
plasticity, it will be interesting to study and answer these new questions. 
 
We found that Homer1b/c (see Chapter 4) was not affected by either lack or induction of 
macroautophagy. Ageta et al. (2001) previously addressed how Homer family proteins are 
degraded in the brain. Interestingly, only short family member Homer1a was found to be 
degraded in a proteasome-dependent manner, whereas long form Homers, including Homer1b/c 
were not degraded via this mechanism. Because we do not know whether other Atg7-
independent degradative pathways are upregulated in our macroautophagy-deficient mice, we 
cannot yet distinguish between two possible interpretations of our results: total striatal 
Homer1b/c levels are 1) not regulated by macroautophagy, or 2) regulated by macroautophagy 
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indirectly through an overcompensation of other degradative processes. Currently, these 
possibilities also apply to PSD95. 
 
Presynaptic consequences of postsynaptic manipulations 
Chronic lack of macroautophagy leads to a clear increase in DAT immunolabel in slices of 
dorsal striatum of 3 month old CKO animals. We propose that a possible explanation for this 
observation. We hypothesized that lack of macroautophagy in medium spiny neurons would lead 
to a larger available pool of proteins, including PSD95, that could contribute to forming part of 
the PSD. Consequently, we would observe a concomitant increase in medium spiny neuron spine 
density. Finally, this would be accompanied by the formation of new synapses, including 
dopaminergic input from the SNc. Indeed, mTOR activation promotes spine formation in 
hippocampal cultures (Lee et al., 2011a). This was accompanied by higher mEPSC frequencies. 
In addition, El-Husseini et al. (2000) reported that overexpression of PSD95 induces an 
enlargement in dendritic spine size and an increment in density. Here also, morphological 
changes on hippocampal neurons are associated with corresponding electrophysiological 
properties. Similar consequences have been reported in studies examining how recreational drugs 
(i.e. amphetamine, cocaine, ketamine, and morphine) modify synapse number and function in 
different parts of the brain (Alcantara et al., 2011; Li et al., 2010; Sarti et al., 2007). In short, 
earlier studies indicate that, in these cases, newly formed spines are incorporated into fully-
functioning synapses. 
 
Whether the increase in DAT is due to a compensatory effect on intra-axonal levels of this 
protein, or to an increase in striatal innervation onto newly formed spines remains to be 
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determined. Remarkably, DA release and reuptake is impaired in several mouse models of 
Huntington’s disease (Johnson et al., 2006; Ortiz et al., 2011). Furthermore, loading of cytosolic 
cargo into autophagic vacuoles is impaired in human cells obtained from patients (Martinez-
Vicent et al., 2010). Of equal importance, it is not known whether these effects on DA 
transmission are caused by neurodegeneration of direct or indirect medium spiny neurons. Future 
studies will be aimed at distinguishing between these possibilities, and have the potential to open 
a new interesting avenue of research in the field of movement disorders. 
 
Medium spiny neurons expressing the D1R in the striatum play a crucial role in motor control, 
learning, and reward. In Parkinson’s disease, the loss of the dopaminergic inputs onto these 
medium spiny and other neurons results in motor impairment. Patients with Huntington’s 
disease, another movement disorder characterized by marked motor dysregulation, show a 
significant degeneration of medium spiny neurons themselves, rather than affecting the 
dopaminergic inputs onto the MSNs (Ross & Tabrizi, 2011). In short, understanding the 
mechanisms governing proper functioning of medium spiny neurons is as crucial as 










Amphetamine and postsynaptic density proteins 
 
INTRODUCTION 
It has been hypothesized that persistent structural modifications in neuronal morphology and 
synaptic reorganization could underlie addiction-type behaviors in humans (Robinson and Kolb, 
1997). Repeated exposure to drugs of abuse including the psychostimulants amphetamine, 
methamphetamine,  methylenedioxymethamphetamine (MDMA), and cocaine are able to 
promote long-lasting structural changes, primarily increases in striatal medium spiny neuron, and 
prefrontal cortex pyramidal neuron spine density and dendritic branching (Ball et al., 2009; Dobi 
et al., 2011; Ferrario et al., 2005; Jedynak et al., 2007; Lee et al., 2006; Muhammad and Kolb, 
2011; Robinson and Kolb, 2004; Roitman et al., 2002; Shen et al., 2009). Although this in vivo 
phenomenon has been studied for years (Robinson and Kolb, 1997), little is known about the 
molecular mechanisms responsible for initiating or maintaining these alterations. This 
knowledge is moreover the result of studies using chronic regimens of cocaine, and not 
amphetamines (Alcantara et al., 2011; Esparza et al. 2012; Norrholm et al., 2003; 
Pulipparacharuvil et al., 2008; Ren et al., 2010; Shen et al., 2009; Toda et al., 2010).  
 
Recent work in rats has demonstrated that cocaine is able to increase spine density faster than 
previously thought, with a single injection being sufficient to give rise to stable spines, resulting 
in an increment in density in the striatum and VTA (Sarti et al., 2007; Shen et al., 2009). Indeed, 
dendritic spines are highly dynamic structures, and their volume, a property associated with 
long-term potentiation, can be modified within seconds in response to glutamatergic input 
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(Kwon and Sabatini, 2011; Murakoshi et al., 2011). However, whereas early studies evaluating 
the effects of chronic psychostimulant regimens on dendritic and spine morphology analyzed 
either cocaine or amphetamine, or compared both (Robinson and Kolb, 1999), more recent 
studies have primarily focused on cocaine. Therefore, how amphetamines modify the density of 
these synaptic structures remains to be evaluated. 
 
Given the critical role of PSD95 in synapse formation and maintenance, it seems highly probable 
that experiences that modify overall levels of PSD95 could alter spine density, and vice versa. In 
support of this hypothesis, environmental enrichment leads to an increase in PSD95 levels in the 
anterior forebrain (Nithianantharajah et al., 2004) using a long term regimen similar to those 
shown to induce increases in spine density in the striatum (Comery et al., 1995). Furthermore, a 
single systemic injection of ketamine increases protein levels of PSD95 with a time course that 
parallels that of transient spine density increases (Li et al., 2010). Consistently, when spine 
density and levels of PSD95 were assessed in the same study, psychostimulant treatments that 
failed to affect PSD95 also fail to modulate spine density or synapse number as assessed by 
electron microscopy (Esparza et al., 2012; Toda et al., 2010; Yao et al., 2004). A similar 
correlation is observed after morphine administration (Pal and Das, 2013). These data support 
the concordance between protein levels of PSD95 and spine density.  
 
Therefore, we used PSD95 as an indirect readout of spine density to determine whether a single 
injection of amphetamine, like cocaine, can induce morphological changes in the striatum in 
vivo. We chose to measure Homer1b/c, a scaffolding molecule that connects PSD95 and its 
binding partners with glutamate mGLURs in the PSD, as a negative control. Homer1b/c belongs 
 76 
 
to the Homer family, which can be divided into short and long variants. While acute 
psychostrimulant treatment has been shown to transiently increase expression of short variants of 
this family, long variants, including Homer1b/c have consistently been shown to remain 
unaffected (Hashimoto et al., 2007; Shaffer et al., 2010; Zhang et al., 2007).  
 
We analyzed the effects of a single intraperitoneal (i.p.) injection of amphetamine on these two 
proteins in a dose (1, 3, 10 and 30 mg/kg) and time (1, 9, 16, 24 and 48 hr)-dependent manner by 
densiometric analysis of western blots. Given that similar treatments with cocaine increase spine 
density on medium spiny (Shen et al., 2009) or ventral tegmental dopaminergic neurons (Sarti et 
al., 2007), we hypothesized that amphetamine would also, and thus, increase overall protein 
levels of PSD95 in the striatum.  
 
In addition, we wanted to explore the role of mTOR in the effects of amphetamine. 
Amphetamine has been shown to positively regulate the activity of mTOR, as observed by 
analysis of its direct downstream effectors (Narita et al., 2005). Moreover, chronic treatments 
with the mTOR inhibitor rapamycin, have been shown to block behavioral effects of both 
cocaine (Bailey et al., 2010; Wu et al., 2011) and methamphetamine (Narita et al., 2005), such as 
locomotor sensitization and conditioned place preference. Hence, we hypothesized that if 
amphetamine increased PSD95 in the striatum, this effect would be dependent on mTOR 
activity.  
 
We found that 1) Homer1b/c was not affected by any amphetamine treatment, 2) amphetamine 
produced a weak dose- and time-dependent increase in levels of PSD95 in the striatum, and 3) 
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due to the fragility of this effect, we were not able to explore the role of mTOR in this 
phenomenon. We conclude that the effect of amphetamine on overall striatal levels of PSD95, an 
indirect readout of spine density, is too small and variable to be useful for further analysis. This 
finding suggests that the increase in spine density that occurs in response to a single injection of 
cocaine might be specific to this drug, and not common to other psychostimulants, and intend in 
follow-up experiments to further explore this issue using chronic exposure to the drugs and 
morphological analysis of spines. 
 
METHODS 
Animals. C57BL/6 male mice aged 8-10 weeks were purchased from Jackson Labs (Bar Harbor, 
ME). Mice were housed in groups of 2-5 in a 12:12 hr light-dark cycle and given access to food 
and water ad libitum. All procedures were approved by, and performed in accordance with the 
Institutional Animal Care and Use Committee at Columbia University.  
 
Drug treatments. Animals were injected with amphetamine during the first 3 hours of the light-
dark cycle.  Socially-housed mice (2.5-5.5 months of age) were removed from their home cage, 
weighed, injected with amphetamine (1, 3, 10 or 30 mg/kg at 2 µl/g of mouse) or 1X PBS (2 µl/g 
of mouse) at zeitgeber (ZT) 1-2 and transferred to a new cage to be housed individually. Mice 
were then returned to standard animals facilities until time of sacrifice. Amphetamine (d-
amphetamine sulfate, Sigma) was dissolved in 1X PBS, and injections were delivered 
intraperitoneally. Animals that were pre-treated with DMSO (1 or 2 µl/g of mouse), received an 
intraperitoneal injection daily for 7 days at ZT8. The protocol for the group of animals treated 




Striatal protein collection. Male wild-type mice were sacrificed by cervical dislocation, total 
striatum was excised in cold 1X PBS, and transferred to an Eppendorf tube containing lysis 
buffer [EDTA-free protease inhibitor mixture (1 tablet/10 ml; Roche), phosphatase inhibitor 
cocktail 2 (1:100; Sigma) in RIPA buffer (Sigma)] and stored at -20°C. Striatal tissue was 
sonicated on ice with a dismembrator, centrifuged at 14 krpm for 10 min, and the pellet was 
discarded, followed by boiling of the supernatant at 100°C for 5 min. Protein concentration was 
determined by the BCA (Pierce, Brebieres, France) method. Protein was then mixed with 4X 
loading buffer (40% glycerol, 8% SDS, 20% β-mercaptoethanol, 0.1% bromophenol blue, 250 
mM Tris base, pH 6.75) and stored in -20°C. 
 
Western blot. A total of 25 µg (or 12.5, 18.75, 25.0, 31.25, 37.5, and 50 µg for the linear range 
experiment in Figure 4.1 of total protein in loading buffer was boiled at 100°C for 5 min and 
loaded in each well of a 10% bisacrylamide (Biorad) gel and run at 180-200 mV for 1 hr or until 
the protein ladder markers (Fisher) were well separated. Protein was transferred to a methanol-
activated PVDF (Millipore) membrane at 40 mV for 3 hr or at 10 mV overnight. Membranes 
were then rinsed and washed once in 1X TBS/0.05% Tween-20, blocked in 5% milk and 
incubated with the following primary antibodies: 1:60000 anti-mouse beta-actin (Sigma), 1:1000 
anti-rabbit PSD95 (Abcam) and anti-rabbit Homer1b/c (Santa Cruz). Blots were washed, 
incubated for 30 min with goat HRP-conjugated anti-mouse or anti-rabbit (Thermoscientific) 
secondary antibodies at a concentration of 1:10000, and re-washed. Protein bands were detected 
by chemiluminescence (Millipore) and quantified by densiometry (Image J). Results were 
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compared using a Student’s t-test (VEH vs. amphetamine), or by 1-way ANOVA followed by 
the Bonferroni post-hoc test. Data on figures is presented as mean ± SEM.  
 
RESULTS 
Acute administration of amphetamine on striatal levels of PSD95 and Homer1b/c 
Before assessing how PSD95 and Homer1b/c are affected by amphetamine, we examined 
whether changes in these proteins were detected reliably by western blot. Gel lanes were loaded 
with 50% increments of protein, starting with 12.5 µg of total protein (Figure 4.1a). 
Densitometric analysis of membranes blotted with antibodies against PSD95, Homer1b/c, or 
actin revealed that the amount of protein (25 µg) that we load in our western blot gels is in the 
linear range of detection. This indicates that our protocol can distinguish between a reduction or 






Figure 4.1 Linear range curves for PSD95, Homer1b/c and Actin Striatal homogenates were 
collected from untreated wild-type mice.  Protein concentration was determined by the BCA 
method. (a.) SDS-PAGE gel lanes were loaded with 12.50, 18.75, 25.00, 31.25, 38.75 or 50.00 
µg of total protein and blotted for PSD95, Homer1b/c and actin. (b.) Bands were quantified by 
densiometry and plotted as actual ratio (value obtained for “x” µg/value obtained for 25 µg) 
versus theoretical ratio (“x” µg/25 µg).  Note that decreases of up to 50%, and increases of up to 
100% are discernable when 25 µg of total protein are analyzed by western blot (n~5 per group). 
The data are expressed as mean values ± SEM. 
 
 
Having confirmed that changes in scaffold proteins PSD95 and Homer1b/c are detectable using 
western blot, we collected striatal tissue of animals treated with amphetamine. We found that 
overall levels of PSD95 in the striatum are significantly increased to 155.8 ± 16.8% of vehicle 
(102.6 ± 6.4% p<0.05) 24 hr after a single injection of amphetamine (i.p. 10 mg/kg). This effect 
is specific to this dose as 1 (117.3 ± 10.7%), 3 (VEH: 100.1 ± 15.1%; 3 mg/kg: 101.0 ± 12.0%) 
and 30 (119.1 ± 9.1%) mg/kg of amphetamine failed to modulate PSD95 (Figures 4.2 and 3). 
The effect is also time-specific as amphetamine (i.p. 10 mg/kg) fails to induce any change in 
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PSD95 at the 1, 9, 16, or 48 hr time point. Finally, the effect of amphetamine is specific to 
PSD95, as levels of Homer1b/c were not affected by any treatment.  
 
 
Figure 4.2 A single injection of amphetamine can increase levels of PSD95, but not 
Homer1b/c in the striatum Striatal homogenates were collected 1, 9, or 24 hr after wild-type 
mice were treated with amphetamine (i.p. at indicated mg/kg) and analyzed for levels of PSD95 
(a.) and Homer1b/c (b.). Results show that amphetamine increases postsynaptic spine proteins 
dose-, time-, and type-dependently. Note how levels of PSD95 are significantly increased when a 
dose of 1 mg/kg amphetamine is administered, and protein is collected at the 24 hr time point. 
The quantified data are expressed as mean values ± SEM percent of vehicle-injected animals. 
Number of animals used per condition are indicated below each set of columns. *p<0.05 versus 





While a single time and dosage provided a ~50% increase in PSD95, the effect of amphetamine 
was inconsistent across experimental groups and western blot runs. To assess whether this was a 
robust response, a new group of mice (n~7 per condition) were injected i.p. with 10 mg/kg of 
amphetamine, striatal tissue was collected 24 hr after treatment, and overall striatal protein levels 
of PSD95 and Homer1b/c were analyzed by western blot (Figure 4.3). In this second set of 
animals, amphetamine did not affect overall levels of PSD95 (control: 100.1% ± 15.1; 10 mg/kg: 
102.9% ± 16.6), nor of Homer1b/c (control: 114.3% ± 21.5; 10 mg/kg: 110.4% ± 14.7). At a 
dose of 3 mg/kg, levels of PSD95 and Homer1b/c remained unaffected at the 24 hr time point. 
We examined whether a stronger effect could be unmasked by analyzing an additional point in 
time before and after 24 hr. Once more, amphetamine did not modify PSD95 or Homer1b/c at 16 





Figure 4.3 Effects of additional amphetamine time and dose points on striatal PSD95 and 
Homer1b/c Striatal homogenates were collected 16 (a.), 24 (b.), or 48 hr (c.) after wild-type 
mice were treated with amphetamine (i.p. at indicated mg/kg) and analyzed for levels of PSD95. 
There was no difference (n~8) in PSD95 or Homer1b/c levels when comparing vehicle-injected 
and amphetamine-injected animals, including a repetition of the 10 mg/kg at 24 hr experiment 
(n=7). The quantified data are expressed as mean values ± SEM percent of vehicle-injected 
animals and were quantified by Student’s t-test or 1-way ANOVA. 
 
 
In a final attempt to reproduce the weak effect of on PSD95 24 hr after a single injection of 
amphetamine, we treated a new set of animals. However, for this experiment we pretreated them 
with DMSO daily for 7 days, then followed by amphetamine. DMSO is used to dissolve 
rapamycin before injecting into animals. If we could observe the effect on PSD95 in these 
animals, this would have controlled for mouse handling, and for the solvent that rapamycin is 
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diluted in. We could then compare data from these animals to answer whether mTOR activity is 
required for the amphetamine-mediated increase in PSD95 in the striatum.  
 
 
Figure 4.4 Acute amphetamine does not affect striatal levels of PSD95 and Homer1b/c in 
animals pretreated with DMSO (a.-b.) Striatal homogenates were collected from wild-type 
mice 24 hr after a single injection of amphetamine (AMPH; i.p. at 10 mg/kg) in animals 
pretreated for 7 days with the vehicle for rapamycin, DMSO (2 µl/g) (a.) or DMSO (1 µl/g) (b.), 
and analyzed for levels of PSD95 and Homer1b/c. There was no difference (n~8) in PSD95 or 
Homer1b/c levels when between DMSO + saline- and DMSO + amphetamine-injected animals. 
The data are expressed as mean values ± SEM percent of vehicle-injected animals and evaluated 




Due to concerns about DMSO toxicity, we pretreated mice with 2 (Figure 4.4a) or 1 µl/g 
(Figure 4.4b) DMSO daily for 7 days. On the seventh day, mice were injected with vehicle or 
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amphetamine. Consistent with our first attempt to replicate effect on amphetamine on PSD95 
(see Figure 4.2), results showed that amphetamine did not increase PSD95 in the striatum of the 
higher (100.0 ± 8.3%; 105.8 ± 19.1%) or lower (99.8 ± 12.3%; 78.0 ± 13.6%)-dosed of DMSO-
pretreated animals. In conclusion, amphetamine does not produce a sufficiently robust effect on 
PSD95 in the striatum. Consequently, we were not able to test for the involvement of mTOR in 
this phenomenon. 
 
Chronic administration of amphetamine on striatal levels of PSD95 and Homer1b/c 
Next, we examined the effect of chronic amphetamine on total protein levels of PSD95 and 
Homer1b/c in the striatum. We used a regimen analogous to that previously employed to 
examine the effect of cocaine on spine density separately in the direct and indirect pathway (Lee 
et al., 2006). The experiment was conducted in a manner that would allow us, if either proteins’ 
levels were affected, to explore the role of mTOR (see Figure 4.5a). We monitored the mice 
throughout the 4 week treatment period to ensure that amphetamine-treated mice did not lose ≥ 
20% of their weight. We observed a time-dependent weight decrease in both vehicle and 
amphetamine-treated mice (Figure 4.5b). There was no difference in the total weight lost 
between the two groups (5.4 ± 1.3 % in VEH vs. 5.1 ± 1.3 % in AMPH-treated mice; p>0.05; 
Student’s t-test). Preliminary data showed that PSD95 is unmodified, but Homer1b/c is 
decreased in response to chronic amphetamine (Figure 4.5b and c). At this writing, additional 
animals are currently being added to this experiment to increase the number of “n’s”. However, 
the fact that a significant effect is already present in vivo in such a small group promises that in 





Figure 4.5 Chronic amphetamine administration reduces levels of Homer1b/c in the 
striatum (a.) Wild-type mice were injected daily with amphetamine (4 mg/kg) from day 1-5. Six 
hours after amphetamine (n~9), an injection of DMSO (2 µl/g; n=8) was also administered on 
days 2 and 5. Animals were left undisturbed for two days, and this regimen was repeated for 3 
more weeks. On day 29, striatal tissue was collected for western blot analysis. (b.) Animals were 
weighed on day 1, 15 and 29, and displayed a significant decrease in weight irrespective of 
whether they received vehicle or amphetamine (p<0.0001). The data are expressed as mean 
values ± SEM percent of vehicle-injected animals and were analyzed by repeated measures 2-
way ANOVA. (c.-d.) Striatal homogenates were analyzed for levels of PSD95 and Homer1b/c. 
Preliminary data shows there was no significant difference (n~6) in PSD95 when between 
DMSO + VEH and DMSO + AMPH-injected. In contrast, Homer1b/c is significantly reduced by 
amphetamine in the striatum (p<0.05). The data are expressed as mean values ± SEM percent of 





A body of literature shows that treatment with psychostimulants can alter neuronal morphology 
in the basal ganglia and limbic system. Although this might be a common feature of chronic 
psychostimulant regimens, it is possible that immediate consequences might differ between 
specific drugs and brain regions. For example, Shen et al. (2009) showed a transient increase in 
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spine density in the striatum at 6 hr after a single injection of cocaine; this change was absent at 
24 hr. Sarti et al. (2007) also detected an increase at 24 hr in the VTA. Limited information 
exists about the mechanisms underlying this specific type of neuroplasticity. Interestingly, 
several studies suggest a close relationship between spine density and levels of PSD95. To our 
knowledge, this is the first study to carefully explore the effect of amphetamine on total levels of 
PSD95 in the brain. This is an important avenue to explore as analyzing spine density, or any 
single measure cannot present a complete picture of synapse, circuit, or animal behavior (Russo 
et al., 2010). Notably, the size of PSD95 clusters are correlated with AMPA receptor levels and 
AMPA-mediated currents (El-Husseini et al., 2000, 2002; Schnell et al., 2002). Finally, PSD95 
content is correlated to PSD and spine size, two important measures of synaptic strength (Aoki et 
al., 2001; Harris and Stevens, 1989). In light of the relevance of this scaffold protein, altogether, 
our data provides a springboard to begin comparing other synapse-related properties in parallel 
with spine density changes in the basal ganglia. 
 
This study was originally designed to test whether the effect of amphetamine on spine density 
could be mediated through increases in the available pool of postsynaptic density proteins; 
specifically, the postsynaptic density protein PSD95. We also explored the potential role of the 
protein Homer1b/c in amphetamine-induced neuroplasticity. For the acute experiments, we 
employed Homer1b/c as a negative control, as several studies have shown that this protein 
remains unaffected by acute cocaine or amphetamine. We hypothesized that the effect of 
amphetamine on these proteins would be mediated by a decrease in mTOR-regulated 
macroautophagic degradation. When active, mTOR induces protein translation and negatively 
regulates the protein and organelle degradation process of macroautophagy. Accordingly, when 
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blocking mTOR activity, protein translation is blocked and macroautophagy is induced. 
Therefore, if involved in my specific PSD95 effect, the interaction between amphetamine and 
mTOR could be due to enhanced protein synthesis, decreased degradation, or both mechanisms. 
 
Previous studies using acute psychostimulant treatments demonstrated that Homer1b/c levels are 
not changed within the spine; it remained unknown, however, whether total cell levels 
themselves were affected. One study showed that while a single dose of cocaine (20 mg/kg) was 
sufficient to induce a time- and dose-dependent elevation in Homer1a, but not of Homer1b/c in 
synaptosomal preparations of the dorsal or ventral striatum (Zhang et al., 2007). Similar findings 
have been observed with amphetamine (5 mg/kg) (Shaffer et al., 2010). In addition, total striatal 
Homer1b/c mRNA levels remain unaffected after a single administration of methamphetamine 
(40 mg/kg) (Hashimoto et al., 2007). As hypothesized, total striatal protein levels of Homer1b/c 
were unaffected by all of our acute amphetamine treatments. However, preliminary data showed 
that Homer1b/c was significantly reduced by a chronic regimen. This is in accord with a study by 
Swanson et al. (2001) where animals were administered cocaine daily for a week and analyzed 
for total Homer1b/c protein after a three week period. Thus, our data on overall striatal levels of 
Homer1b/c protein complements psychostimulant-induced changes in Homer1b/c mRNA, and is 
consistent with what is occurring with protein levels in synaptosomes.  
 
To our knowledge, there are no studies on the acute effects of amphetamine on PSD95 or spine 
density, and only a few studies address the effect of chronic administration of psychostimulants. 
Therefore, it is difficult to compare to our data with earlier studies, and while psychostimulants 
act to acutely increase extracellular DA levels, we have yet to identify a common postsynaptic 
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morphological response to acute exposure to psychostimulants. Comparisons are further 
complicated due to differences in experimental design, including the number of drug 
administrations, the length of the withdrawal period after exposure, and the tissue from which 
protein was harvested. Shibasaki et al. (2011) reported an increase in forebrain levels of PSD95 
after 3 injections of methamphetamine (1 mg/kg; administered every 2 days). In the case of 
cocaine, a 5-day regimen resulted in lower levels of PSD95 in striatal tissue. However, this was 
observed after a period of 2 weeks following the last injection, and might not represent effects 
directly caused by cocaine (Yao et al., 2004). When we treated mice chronically with 
amphetamine, we did not observe a significant change in levels of striatal PSD95, although 
altered Homer1b/c levels may be more robust. This data is preliminary, however, and will 
require replication with more animals per group before making any conclusions. 
 
In summary, while we constructed an elaborate analysis of time- and dose-dependent effects of 
amphetamine on overall striatal levels of both PSD95 including up to 5 time points (1, 9, 16, 24 
and 48 hr after a single dose) and 4 different doses (1, 3, 10 and 30 mg/kg) of amphetamine, the 
data did not demonstrate a robust modulation of PSD95 by acute amphetamine, in contrast to out 
hypothesis and indications from the literature. In detail, an initial experiment (n~20) revealed a 
time (24 hr), dose (10 mg/kg) and protein (PSD95)-specific effect of amphetamine, but when the 
exact experiment was repeated (n~7), we were not able to observe the effect. We conclude that 
the effect of amphetamine on PSD95 is insufficiently robust for our study and due to variability 
in animals or technique, ma require a prohibitive number of animals (n~20) per condition to be 
pursued. Thus, the inability to reproduce the effect of acute amphetamine on overall striatal 
levels of PSD95 precluded us from investigating the role of mTOR, and macroautophagy on 
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PSD95. Consequently, future studies will be aimed at directly examining the effect of 
amphetamine of dendritic spine morphology, and on the effect of chronic amphetamine regimen 























CHAPTER 5  
Discussion 
 
Summary and Conclusions 
The master regulatory kinase known as mTOR is well known to regulate both protein synthesis 
and macroautophagy-dependent degradation of cytosolic components. mTOR activity has also 
long been implicated in regulating synaptic plasticity. Our data demonstrates an important role 
for macroautophagy on neurodegeneration. While a role for mTOR in synaptic plasticity by 
enhancing protein translation has been reported in multiple studies, mTOR’s potential role in 
modulating synaptic function through macroautophagy remained unexplored. To investigate this 
possibility we chose to study synaptic function in the striatum.  
 
First, we analyzed how modulation of macroautophagy affected the presynaptic morphology and 
function in the midbrain dopaminergic neuron. The advantages of this system are that 
neurotransmitter release and reuptake can be measured directly by cyclic voltammetry 
independently of postsynaptic responses, and that the corticostriatal slice preparation provides a 
system in which functional dopaminergic terminals can be isolated from somatodendritic regions 
for up to 7 hr. We generated mutant mice (DAT-Cre+/-; Atg7fl/fl) deficient for macroautophagy by 
crossing a line that expressed Cre recombinase under the control of DAT to another with a floxed 




Under electron microscopy, we found that TH-labeled dopaminergic axonal profiles in the dorsal 
striatum of 2 month old CTL and CKO mice possessed a similar number of dopaminergic 
synaptic terminals, but that the axonal profile area was ~one third larger in the mutant mice. 
Rapamycin-induced mTOR inhibition in vivo caused a ~30% reduction in TH profile size in CTL 
mice, but had no effect in CKO animals. Thus, both basal and induced macroautophagy control 
dopaminergic axonal profile volume in the striatum. 
 
As dopaminergic terminals in the striatum compose only a small fraction of the total number of 
terminals in this area, we used the false neurotransmitter 5-OHDA to selectively label DA 
synaptic vesicles. Dopaminergic synaptic vesicle density was decreased by ~25% with acute 
rapamycin treatment in wild-type and CTL mice, but not in CKO mice, consistent with a role for 
macroautophagy in the regulation of dopaminergic vesicular contents. Consistently, evoked DA 
release as measured by cyclic voltammetry was ~50% higher in CKO corticostriatal slices than 
in CTLs. DA release was decreased by ~25% with rapamycin in CTL animals, but not in 
mutants. The mutants also exhibited more rapid recovery of evoked DA release. Thus, both basal 
and induced macroautophagy can place a brake on presynaptic activity in vivo, perhaps by 
regulating the turnover of synaptic vesicles. 
 
These conclusions were supported by the observation that wild-type rapamycin-treated 
corticostriatal slices exhibited a transient increase in LC3ii, a phenomenon characteristic of 
macroautophagic flux. We also note that rapamycin induced presynaptic macroautophagy 
generally, producing more striatal synaptic profiles with autophagosome-like vacuoles and 
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decreasing synaptic terminal area and the number of synaptic vesicles in both dopaminergic and 
nondopaminergic terminals. Mutants also contained a larger number of mitochondria per 
terminal area. Thus, suggesting that macroautophagy can act globally in the striatum, and in 
other brain regions to modify presynaptic morphology and function. 
 
To expand on this work, we recently generated a second line of macroautophagy-deficient 
animals (D1R-Cre+/-; Atg7fl/fl) using the Cre-loxP system. We verified that these mice cannot 
activate macroautophagy in D1R-expressing medium spiny neurons regions by detection of p62, 
a well-established substrate of autophagosomes. Coexpression of DARPP32 and substance P in 
p62+ neurons confirmed that, as expected, lack of macroautophagy is only observed in direct 
pathway medium spiny neurons, and is mostly absent in the ventral striatum. This model 
provides advantages over other medium spiny neuron CKO mouse lines: 1) other D1R-Cre lines 
express Cre in adult D2R+ neurons in addition to being present in the direct pathway (Lemberger 
et al., 2007) and 2) the low expression of Cre in the ventral striatum provides an internal control 
in the striatum of CKO mice. 
 
PSD size is highly correlated to synaptic strength (Russo et al., 2010). Thus, this mouse line 
provides a new model to study the role of macroautophagy in neuroplasticity in the striatum and 
basal ganglia. We examined PSD size and density in the dorsal striatum by electron microscopy 
and found that 2 month old mutants have ~20% larger PSDs but no difference in the number of 
excitatory synapses (PSDs) at this age. As we could not determine whether dendritic spines 
containing these PSDs were D1 or D2R+, the observed increase in their size is probably an 
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underestimation of the effect that absence of macroautophagy has on this particular postsynaptic 
measure. This data suggests that apart from playing a role in presynaptic morphology and 
neurotransmission, macroautophagy can also modulate properties of the postsynaptic 
environment.  
 
Our results demonstrate that macroautophagy plays multiple roles in presynaptic and 
postsynaptic function in the striatum, including the turnover and degradation of synaptic vesicles, 
regulation of terminal volume and PSD size, and the kinetics of transmitter release. Given the 
knowledge gained in these studies, an important future goal will be to elucidate the mechanisms 
by which macroautophagy can affect physiological and behavioral measures of neuroplasticity, 
especially those already shown to be modulated by mTOR activity. Finally, our study opens the 
door for future research on the role of macroautophagy in basal and induced modulation of 
mTOR in overall synaptic structure and function, and suggests further reasons to explore its role 
in diseases of the nervous system. 
 
Future Directions 
Lack of macroautophagy expressed as accumulation of p62+ aggregates in D1R-rich regions is 
robustly expressed in the dorsal striatum and deep layers of the cortex. This phenotype was 
visible earlier in the cortex and later in the striatum. This opens several interesting directions. We 
can answer whether CKO neurons in these two regions are in fact dying or not. It also remains 
unknown whether striatal (including glutamatergic and dopaminergic) and midbrain 
(GABAergic) neurotransmission is affected by macroautophagy deficiency in direct pathway 
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medium spiny neurons. This also applies to striatal glutamatergic and midbrain somatodendritic 
transmission kinetics in animals with macroautophagy-deficient dopaminergic neurons. 
 
Preliminary data from D1R-Cre+/-; Atg7fl/fl suggests that these mice exhibit early signs of 
neurodegeneration. We have crossed this line to mice containing floxed reporter genes to 
confirm loss of direct pathway neurons. Parallel stereological analysis of the dorsal striatum 
would also prove informative. Results indicative of differing levels of vulnerability to lack of 
macroautophagy in the different affected cells in our mutants will add to the studies that have 
reported on neuronal damage and loss in Atg7 CKOs (Hara et al., 2006; Inoue et al., 2013; 
Komatsu et al., 2005, 2006, 2007). In particular, a battery of behavioral tests in mice that lack of 
Atg7 in dopaminergic neurons have shown that these mice could serve as a progressive model of 
Parkinson’s disease in mice (Ahmed et al., 2012; Inuoe et al., 2013). Our new medium spiny 
neuron line holds the same potential to explain certain aspects of Huntington’s disease, in which 
clearance of mitochondria and lipid droplets is disturbed (Martinez-Vicente et al., 2010). 
 
Finally, one particular reason to generate and characterize these mouse lines has been to study 
the specific role of macroautophagy in the context of drugs of abuse, in particular the 
psychostimulants cocaine and amphetamine, which fail to sensitize animals to its locomotor and 
conditioned place preference-inducing effects if accompanied by mTOR inhibition (Bailey et al., 
2010; Narita et al., 2005; Wu et al., 2011). Amphetamine have been reported to increase mTOR 
activity (Bailey et al., 2010; Narita et al., 2005; Wu et al., 2011) and disrupt lysosomal function 
(Talloczy et al., 2008). Accordingly, it will be valuable to determine whether macroautophagic 
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degradation, independently of other mTOR-modulated processes, plays a role in the plethora of 
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